Anti-AVB6 antibodies, compositions comprising Anti-AVB6 antibodies and methods of making and using Anti-AVB6 antibodies
Antibodies with improved affinity and specificity for avP6 address the limitations of current therapies by enhancing treatment efficacy and safety in cancers, particularly NSCLC, HNSCC, and esophageal cancers, through targeted modulation of avP6 activity.
Patent Information
- Application Number
- PCT/US2026/027116
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Current anti-avP6 therapeutic agents face challenges such as dose-limiting systemic toxicities and on-target toxicities, particularly in treating cancers like NSCLC, HNSCC, and esophageal cancers, necessitating the development of therapeutics with improved affinity and specificity for avP6 to enhance treatment efficacy while minimizing side effects.
Development of antibodies that selectively bind to avP6 with improved affinity and specificity, including variants with conservative amino acid substitutions, and their conjugates, for use in pharmaceutical compositions and diagnostic methods, targeting and modulating avP6 activity to treat and diagnose diseases like cancers.
The antibodies provide enhanced therapeutic responses in heterogeneous or low-avP6-expressing tumors with reduced systemic and on-target toxicities, offering improved treatment options for cancers.
Smart Images

Figure US2026027116_12112026_PF_FP_ABST
Abstract
Description
Attorney Docket No. 108843.00624ANTI-AVB6 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-AVB6 ANTIBODIES AND METHODS OF MAKING AND USING ANTI-AVB6ANTIBODIESCROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of, and priority to, U. S. Provisional Application No. 63 / 801,594, filed May 7, 2025, the entirety of which is hereby fully incorporated herein by reference.FIELD OF THE INVENTION
[0002] The present disclosure generally relates to antibodies and antibody conjugates with binding specificity for Integrin avP6 (avP6) and compositions comprising the antibodies or antibody conjugates, including pharmaceutical compositions, diagnostic compositions, and kits. Also provided are methods of making anti-avP6 antibodies and antibody conjugates, and methods of using anti-avP6 antibodies and antibody conjugates, for example, for therapeutic purposes, diagnostic purposes, and research purposes.BACKGROUND
[0003] Integrin avP6 is a heterodimer formed by Integrin 6 (ITGB6) and Integrin av. ITGB6 is an activator of TGF-P and plays a crucial role in cell adhesion, migration and motility. ITGB6 has normal low constitutive expression limited to epithelial lining in the gastrointestinal tract, lung, kidney, urinary bladder and salivary gland. Lyon RP et al., Mol Cancer Ther. 2023 Dec 1;22(12): 1444-1453. Expression of ITGB6 is also upregulated during wound repair and tissue remodeling. Functionally, ITGB6 has been reported to prevent anoikis and to promote epithelial to mesenchymal transition. Ramos et al. Anticancer Res. 2009 Jan;29(l): 125-30. In the clinic, sigvotatug vedotin (SV, Seagen / Pfizer), a DAR4 mc-val-cit-pAB-MMAE ADC, has observed anti-tumor response in NSCLC, HNSCC, and esophageal cancers. Peters S., et al., Journal of Clinical Oncology, Vol 42, No. 16_suppl (ASCO 2024 Abstract). Current anti-avP6 therapeutic agents face challenges, e.g., dose-limiting systemic toxicities, such as diarrhea and neutropenia, and on-target toxicities, such as stomatitis.
[0004] There is a need for therapeutics and methods of targeting and / or modulating the activity and safety of anti-avP6 agents in treating and diagnosing diseases, such as cancers.11107438300\1\AMERICASAttorney Docket No. 108843.00624SUMMARY
[0005] Provided herein are antibodies that selectively bind avP6. In some embodiments, the anti-avP6 antibodies disclosed herein have improved affinity and specificity (e.g., certain antibodies do not interfere with the TGF-P signaling) and / or improved responses (e.g., certain antibodies have responses in heterogenous or low-avP6-expressing tumors).
[0006] In some embodiments, the antibodies bind human avP6. In some embodiments, the antibodies also bind homologs of human avP6. In some embodiments, the antibodies bind cynomolgus monkey avP6. In some embodiments, the antibodies also bind homologs of cynomolgus monkey avP6. In some embodiments, the antibodies bind murine avP6. In some embodiments, the antibodies also bind homologs of murine avP6.
[0007] In some embodiments, the antibodies comprise, consist essentially of, or consist of, an illustrative CDR, framework, VH, or VL, heavy chain or light chain, or combination thereof, sequence provided in this disclosure, or a variant thereof. In some aspects, the variant is a variant with one or more conservative amino acid substitutions. In some aspects, the variant has sequence identity to the illustrative sequence or sequences. In some embodiments, provided herein are conjugates of the antibodies.
[0008] Also provided are compositions and kits comprising the antibodies or antibody conjugates described herein. In some embodiments, the compositions are pharmaceutical compositions. Any suitable pharmaceutical composition may be used. In some embodiments, the pharmaceutical composition is a composition for parenteral administration.
[0009] This disclosure also provides methods of using the anti-avP6 antibodies or antibody conjugates provided herein. In some embodiments, the methods are methods of treatment. In some embodiments, the methods are diagnostic methods. In some embodiments, the methods are analytical methods. In some embodiments, the methods are methods of purifying and / or quantifying avP6.
[0010] In some embodiments, the antibodies or antibody conjugates are used to treat a disease or condition. In some aspects, the disease or condition is a cancer.BRIEF DESCRIPTION OF THE FIGURES
[0011] FIG. 1 provides a comparison of the Kabat and Chothia numbering systems for CDR-Hl. Adapted from Martin A. C. R. (2010). Protein Sequence and Structure Analysis of Antibody Variable Domains. In R. Kontermann & S. Diibel (Eds.), Antibody Engineering vol. 2 (pp. 33-51). Springer-Verlag, Berlin Heidelberg.21107438300\1\AMERICASAttorney Docket No. 108843.00624
[0012] FIG. 2 shows the effect of exemplary anti-avP6 antibodies on TGF-P pathway. The effect of the anti-avP6 antibodies on TGF-P pathway was measured using a TGF-P reporter cell line co-cultured with ITGB6 positive Shmac4 cells. Three anti-avP6 antibodies inhibited the TGF-P pathway similar to LAP while one anti-avP6 antibody did not affect TGF-P pathway.
[0013] FIGS. 3A and 3B show anti-avP6 antibodies internalization activity on HCC38 cells. Anti-avP6 antibodies internalization activity was measured by live imaging using ITGB6 positive HCC38 cells.DETAILED DESCRIPTION OF THE EMBODIMENTS1. DEFINITIONS
[0014] Unless otherwise defined, all terms of art, notations and other scientific terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this invention pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and / or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a difference over what is generally understood in the art. The techniques and procedures described or referenced herein are generally well understood and commonly employed using conventional methodologies by those skilled in the art, such as, for example, the widely utilized molecular cloning methodologies described in Sambrook et al., Molecular Cloning: A Laboratory Manual 2nd ed. (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. As appropriate, procedures involving the use of commercially available kits and reagents are generally carried out in accordance with manufacturer-defined protocols and conditions unless otherwise noted.
[0015] As used herein, the singular forms “a,” “an,” and “the” include the plural referents unless the context clearly indicates otherwise.
[0016] The term “about” indicates and encompasses an indicated value and a range above and below that value. In certain embodiments, the term “about” indicates the designated value ± 10%, ± 5%, or ± 1%. In certain embodiments, the term “about” indicates the designated value ± one standard deviation of that value.
[0017] The term “combinations thereof’ includes every possible combination of elements to which the term refers to. For example, a sentence stating that “if 012 is A, then as is not D; as is not S; or ae is not S; or combinations thereof includes the following combinations when a? is A: (1) as is not D; (2) as is not S; (3) ae is not S; (4) as is not D; as is not S; and ae is not S; (5) as is not D and as is not S; (6) as is not D and ae is not S; and (7) as is not S and ae is not S. In another example, if a set of antibody heavy chains comprise {A, B, and C} and a set of antibody31107438300\1\AMERICASAttorney Docket No. 108843.00624light chains comprise {D, E, and F} then the potential combinations of heavy and light chains comprise the set of {AD, AE, AF, BD, BE, BF, CD, CE, and CF}.
[0018] The term “Integrin avP6” or “avP6” refers to the protein complex formed by heterodimerization of Integrin P6 (ITGB6) and Integrin av (ITGAV). The term “ITGB6” refers to, unless specified otherwise, any variants, isoforms and species homologs of human ITGB6 proteins that are naturally expressed by cells, or that are expressed by cells transfected with a ITGB6 gene. ITGB6 proteins include, for example, human ITGB6 (SEQ ID NO: 1, UniProt Accession No. Pl 8564). In some embodiments, ITGB6 proteins include cynomolgus monkey ITGB6 (SEQ ID NO: 2, UniProt Accession No. A0A2K5TZ36). In some embodiments, ITGB6 proteins include murine ITGB6 (SEQ ID NO: 3, UniProt Accession No. Q9Z0T9). The term “ITGAV” refers to, unless specified otherwise, any variants, isoforms and species homologs of human ITGAV proteins that are naturally expressed by cells, or that are expressed by cells transfected with a ITGAV gene. ITGAV proteins include, for example, human ITGAV (SEQ ID NO: 1512, UniProt Accession No. P06756). In some embodiments, ITGAV proteins include cynomolgus monkey ITGB6 (SEQ ID NO: 1513, UniProt Accession No. A0A2K5WCD3). In some embodiments, ITGAV proteins include murine ITGB6 (SEQ ID NO: 1514, UniProt Accession No. P43406).
[0019] The term “immunoglobulin” refers to a class of structurally related proteins generally comprising two pairs of polypeptide chains: one pair of light (L) chains and one pair of heavy (H) chains. In an “intact immunoglobulin,” all four of these chains are interconnected by disulfide bonds. The structure of immunoglobulins has been well characterized. See, e.g., Paul, Fundamental Immunology 7th ed., Ch. 5 (2013) Lippincott Williams & Wilkins, Philadelphia, PA. Briefly, each heavy chain typically comprises a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region typically comprises three domains, abbreviated CHI, CH2, and CH3. Each light chain typically comprises a light chain variable region (VL) and a light chain constant region. The light chain constant region typically comprises one domain, abbreviated CL.
[0020] The term “antibody” describes a type of immunoglobulin molecule and is used herein in its broadest sense. An antibody specifically includes intact antibodies (e.g., intact immunoglobulins), and antibody fragments. Antibodies comprise at least one antigen-binding domain. One example of an antigen-binding domain is an antigen binding domain formed by a VH-VL dimer. An “avP6 antibody,” “anti-avP6 antibody,” “avP6 Ab,” “avP6-specific antibody,” “anti-avP6 Ab,” “avP6 antibody,” “anti-avP6 antibody,” “avP6 Ab,” “avP6-specific antibody,” or “anti-avP6 Ab” is an antibody, as described herein, which binds specifically to avP6. In some41107438300\1\AMERICASAttorney Docket No. 108843.00624embodiments, the antibody binds the extracellular domain of avP6. As used herein, unless otherwise specified, an antibody may also comprise an “antibody fragment” as defined herein.
[0021] The VH and VL regions may be further subdivided into regions of hypervariability (“hypervariable regions (HVRs)” also called “complementarity determining regions” (CDRs)) interspersed with regions that are more conserved. The more conserved regions are called framework regions (FRs). Each VH and VL generally comprises three CDRs and four FRs, arranged in the following order (from N-terminus to C-terminus): FR1 - CDR1 - FR2 - CDR2 -FR3 - CDR3 - FR4. The CDRs are involved in antigen binding, and influence antigen specificity and binding affinity of the antibody. See Kabat et al., Sequences of Proteins of Immunological Interest 5th ed. (1991) Public Health Service, National Institutes of Health, Bethesda, MD, incorporated by reference in its entirety.
[0022] The light chain from any vertebrate species can be assigned to one of two types, called kappa and lambda, based on the sequence of the constant domain.
[0023] The heavy chain from any vertebrate species can be assigned to one of five different classes (or isotypes): IgA, IgD, IgE, IgG, and IgM. These classes are also designated a, 8, a, y, and p, respectively. The IgG and IgA classes are further divided into subclasses on the basis of differences in sequence and function. Humans express the following subclasses: IgGl, IgG2, IgG3, IgG4, IgAl, and IgA2.
[0024] The amino acid sequence boundaries of a CDR can be determined by one of skill in the art using any of a number of known numbering schemes, including those described by Kabat et al., supra (“Kabat” numbering scheme); Al-Lazikani et al., 1997, J. Mol. BioL, 273:927-948 (“Chothia” numbering scheme); MacCallum et al., 1996, J. Mol. Biol. 262:732-745 (“Contact” numbering scheme); Lefranc et al., Dev. Comp. Immunol., 2003, 27:55-77 (“IMGT” numbering scheme); and Honegge and Pliickthun, J. Mol. Biol., 2001, 309:657-70 (“AHo” numbering scheme), each of which is incorporated by reference in its entirety.
[0025] Table 1A provides the positions of CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3 as identified by the Kabat and Chothia schemes. Table IB provides the positions of LFR1, CDR-L1, LFR2, CDR-L2, LFR3, CDR-L3, LFR4, HFR1, CDR-H1, HFR2, CDR-H2, HFR3, CDR-H3, and HFR4 as identified by the Kabat and Chothia schemes.Table 1A. Residues in CDRs according to Kabat and Chothia numbering schemes.51107438300\1\AMERICASAttorney Docket No. 108843.00624* The C-terminus of Chothia CDR-H1, when compared to and numbered with the Kabat numbering convention, varies between H32 and H34, depending on the length of the CDR, as illustrated in FIG. 1.Table IB. Residues in CDRs according to Kabat and Chothia numbering schemes.* The C-terminus of Chothia CDR-H1, when numbered using the Kabat numbering convention, varies between H32 and H34, depending on the length of the CDR, as illustrated in FIG. 1
[0026] Unless otherwise specified, the numbering scheme used for identification of a particular CDR herein is the Kabat numbering scheme. Where the residues encompassed by these two numbering schemes diverge (e.g., CDR-H1 and / or CDR-H2) and the scheme is not specified, the numbering scheme is Kabat. For convenience, CDR-H3 is sometimes referred to herein as Kabat CDR-H3, or as Chothia CDR-H3. However, this is not intended to imply differences in sequence where they do not exist, and one of skill in the art can readily confirm whether the sequences are the same or different by examining the sequences.
[0027] CDRs may be assigned, for example, using antibody numbering software, such as Abnum, available atwww.bioinf.org.uk / abs / abnum, and described in Abhinandan and Martin, Immunology, 2008, 45:3832-3839, incorporated by reference in its entirety.61107438300\1\AMERICASAttorney Docket No. 108843.00624
[0028] The “framework region” refers to a subdivision of the variable region acting as a scaffold for the CDRs. Unless specified otherwise, there are four framework regions for each heavy chain and light chain, wherein each CDRs is flanked by one framework region. Unless stated otherwise, the numbering of the framework region is based on using either the Kabat or Chothia numbering scheme. Table IB provides the positions of framework positions LFR1, LFR2, LFR3, LFR4, HFR1, HFR2, HFR3, and HFR4 as identified by the Kabat and Chothia schemes.
[0029] The “EU numbering scheme” is generally used when referring to a residue in an antibody heavy chain constant region (e.g., as reported in Kabat et al., supra). Unless stated otherwise, the EU numbering scheme is used to refer to residues in antibody heavy chain constant regions described herein.
[0030] An “antibody fragment” comprises a portion of an intact antibody, such as the antigen binding or variable region of an intact antibody. Antibody fragments include, for example, Fv fragments, Fab fragments, F(ab’)2 fragments, Fab’ fragments, scFv (sFv) fragments, and scFv-Fc fragments.
[0031] “Fv” fragments comprise a non-covalently-linked dimer of one heavy chain variable domain and one light chain variable domain.
[0032] “Fab” fragments comprise, in addition to the heavy and light chain variable domains, the constant domain of the light chain and the first constant domain (CHI) of the heavy chain. Fab fragments may be generated, for example, by recombinant methods or by papain digestion of a full-length antibody.
[0033] “F(ab’)2” fragments contain two Fab’ fragments joined, near the hinge region, by disulfide bonds. F(ab’)2 fragments may be generated, for example, by recombinant methods or by pepsin digestion of an intact antibody. The F(ab’) fragments can be dissociated, for example, by treatment with P-mercaptoethanol.
[0034] “Single-chain Fv” or “sFv” or “scFv” antibody fragments comprise a VH domain and a VL domain in a single polypeptide chain. The VH and VL are generally linked by a peptide linker. See Pliickthun A. (1994). Antibodies from Escherichia coli. In Rosenberg M. & Moore G. P. (Eds.), The Pharmacology of Monoclonal Antibodies vol. 113 (pp. 269-315). Springer-Verlag, New York, incorporated by reference in its entirety.
[0035] scFv-Fc” fragments comprise an scFv attached to an Fc domain. For example, an Fc domain may be attached to the C-terminus of the scFv. The Fc domain may follow the VH or VL, depending on the orientation of the variable domains in the scFv (i.e., VH-VL or VL-VH). Any71107438300\1\AMERICASAttorney Docket No. 108843.00624suitable Fc domain known in the art or described herein may be used. In some cases, the Fc domain comprises an IgGl Fc domain.
[0036] “Single chain Fab” refers to a polypeptide comprising a light chain variable domain, a light chain constant domain, and a heavy chain variable domain. In some embodiments, a single chain Fab comprises or is a “VLCL-VH” fragment comprising comprise VL, CL, and VH domains in a single polypeptide chain. The CL and VH domains are generally linked by a peptide linker.
[0037] The term “monoclonal antibody” refers to an antibody from a population of substantially homogeneous antibodies. A population of substantially homogeneous antibodies comprises antibodies that are substantially similar and that bind the same epitope(s), except for variants that may normally arise during production of the monoclonal antibody. Such variants are generally present in only minor amounts. A monoclonal antibody is typically obtained by a process that includes the selection of a single antibody from a plurality of antibodies. For example, the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, yeast clones, bacterial clones, or other recombinant DNA clones. The selected antibody can be further altered, for example, to improve affinity for the target (“affinity maturation”), to humanize the antibody, to improve its production in cell culture, and / or to reduce its immunogenicity in a subject.
[0038] The term “chimeric antibody” refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.
[0039] “Humanized” forms of non-human antibodies are chimeric antibodies that contain minimal sequence derived from the non-human antibody. A humanized antibody is generally a human immunoglobulin (recipient antibody) in which residues from one or more CDRs are replaced by residues from one or more CDRs of a non-human antibody (donor antibody). The donor antibody can be any suitable non-human antibody, such as a mouse, rat, rabbit, chicken, or non-human primate antibody having a desired specificity, affinity, or biological effect. In some instances, selected framework region residues of the recipient antibody are replaced by the corresponding framework region residues from the donor antibody. Humanized antibodies may also comprise residues that are not found in either the recipient antibody or the donor antibody. Such modifications may be made to further refine antibody function. For further details, see Jones et al., Nature, 1986, 321:522-525; Riechmann et al., Nature, 1988, 332:323-329; and Presta, Curr. Op. Struct. Biol., 1992, 2:593-596, each of which is incorporated by reference in its entirety.81107438300\1\AMERICASAttorney Docket No. 108843.00624
[0040] A “human antibody” is one which possesses an amino acid sequence corresponding to that of an antibody produced by a human or a human cell, or derived from a non-human source that utilizes a human antibody repertoire or human antibody-encoding sequences (e.g., obtained from human sources or designed de novo). Human antibodies specifically exclude humanized antibodies.
[0041] An “isolated antibody” is one that has been separated and / or recovered from a component of its natural environment. Components of the natural environment may include enzymes, hormones, and other proteinaceous or nonproteinaceous materials. In some embodiments, an isolated antibody is purified to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence, for example by use of a spinning cup sequenator. In some embodiments, an isolated antibody is purified to homogeneity by gel electrophoresis (e.g, SDS-PAGE) under reducing or nonreducing conditions, with detection by Coomassie blue or silver stain. An isolated antibody includes an antibody in situ within recombinant cells, since at least one component of the antibody’s natural environment is not present. In some aspects, an isolated antibody is prepared by at least one purification step.
[0042] In some embodiments, an isolated antibody is purified to at least 80%, 85%, 90%, 95%, or 99% by weight. In some embodiments, an isolated antibody is purified to at least 80%, 85%, 90%, 95%, or 99% by volume. In some embodiments, an isolated antibody is provided as a solution comprising at least 85%, 90%, 95%, 98%, 99% to 100% by weight. In some embodiments, an isolated antibody is provided as a solution comprising at least 85%, 90%, 95%, 98%, 99% to 100% by volume.
[0043] “Affinity” refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g, an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can be represented by the dissociation constant (KD). Affinity can be measured by common methods known in the art, including those described herein. Affinity can be determined, for example, using surface plasmon resonance (SPR) technology, such as a Biacore® instrument. In some embodiments, the affinity is determined at 25°C.
[0044] With regard to the binding of an antibody to a target molecule, the terms “specific binding,” “specifically binds to,” “specific for,” “selectively binds,” and “selective for” a particular antigen (e.g., a polypeptide target) or an epitope on a particular antigen mean binding that is measurably different from a non-specific or non-selective interaction. Specific binding91107438300\1\AMERICASAttorney Docket No. 108843.00624can be measured, for example, by determining the binding of a molecule compared to the binding of a control molecule. Specific binding can also be determined by competition with a control molecule that mimics the antibody binding site on the target. In that case, specific binding is indicated if the binding of the antibody to the target is competitively inhibited by the control molecule.
[0045] The term “ka” (sec-1), as used herein, refers to the dissociation rate constant of a particular antibody-antigen interaction. This value is also referred to as the koff value.
[0046] The term “ka” (M_|*sec-1), as used herein, refers to the association rate constant of a particular antibody-antigen interaction. This value is also referred to as the konvalue.
[0047] The term “KD” (M), as used herein, refers to the dissociation equilibrium constant of a particular antibody -anti gen interaction. KD = kd / ka.
[0048] The term “KA” (M'1), as used herein, refers to the association equilibrium constant of a particular antibody -anti gen interaction. KA = ka / kd.
[0049] An “affinity matured” antibody is one with one or more alterations in one or more CDRs or FRs that result in an improvement in the affinity of the antibody for its antigen, compared to a parent antibody which does not possess the alteration(s). In one embodiment, an affinity matured antibody has nanomolar or picomolar affinity for the target antigen. Affinity matured antibodies may be produced using a variety of methods known in the art. For example, Marks et al. (Bio Technology, 1992, 10:779-783, incorporated by reference in its entirety) describes affinity maturation by VH and VL domain shuffling. Random mutagenesis of CDR and / or framework residues is described by, for example, Barbas et al. (Proc. Nat. Acad. Sci. U. S. A., 1994, 91:3809-3813); Schier et al., Gene, 1995, 169:147-155; Yelton et al., J. Immunol., 1995, 155:1994-2004; Jackson et al., J. Immunol., 1995, 154:3310-33199; and Hawkins et al, J. Mol. Biol., 1992, 226:889-896, each of which is incorporated by reference in its entirety.
[0050] When used herein in the context of two or more antibodies, the term “competes with” or “cross-competes with” indicates that the two or more antibodies compete for binding to an antigen (e.g., avP6). In one exemplary assay, avP6 is coated on a plate and allowed to bind a first antibody, after which a second, labeled antibody is added. If the presence of the first antibody reduces the binding of the second antibody, then the antibodies compete. In another exemplary assay, a first antibody is coated on a plate and allowed to bind the antigen, and then the second antibody is added. The term “competes with” also includes combinations of antibodies where one antibody reduces binding of another antibody, but where no competition is observed when the antibodies are added in the reverse order. However, in some embodiments, the first and second antibodies inhibit binding of each other, regardless of the order in which101107438300\1\AMERICASAttorney Docket No. 108843.00624they are added. In some embodiments, one antibody reduces the binding of another antibody to its antigen by at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.
[0051] The term “epitope” means a portion of an antigen capable of specific binding to an antibody. Epitopes frequently consist of surface-accessible amino acid residues and / or sugar side chains and may have specific three-dimensional structural characteristics, as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents. An epitope may comprise amino acid residues that are directly involved in the binding, and other amino acid residues, which are not directly involved in the binding. The epitope to which an antibody binds can be determined using known techniques for epitope determination such as, for example, testing for antibody binding to variants of αvβ6 with different point-mutations.
[0052] The term “conjugate” or “antibody conjugate” refers to a compound or drug moiety described herein linked to one or more macromolecular moieties. The macromolecular moiety is as defined herein or is any macromolecule deemed suitable to the person of skill in the art. The compound or drug moiety can be any compound or drug moiety described herein. The compound or drug moiety can be directly linked to the macromolecular moiety via a covalent bond, or the compound or drug moiety can be linked to the macromolecular moiety indirectly via a linker. Typically, the linker is covalently bonded to the macromolecular moiety and also covalently bonded to the compound or drug moiety.
[0053] The term “payload” refers to a molecular moiety that can be conjugated to an antibody. In particular embodiments, payloads are selected from the group consisting of therapeutic moieties and labelling moieties.
[0054] The term “linker” refers to a molecular moiety that is capable of forming at least two covalent bonds. Typically, a linker is capable of forming at least one covalent bond to a macromolecular moiety and at least another covalent bond to a compound or drug moiety. In certain embodiments, a linker can form more than one covalent bond to a macromolecular moiety. In certain embodiments, a linker can form more than one covalent bond to a compound or drug moiety or can form covalent bonds to more than one compound or drug moiety. After a linker forms a bond to a macromolecular moiety, or a compound or drug moiety, or both, the remaining structure (i.e. the residue of the linker (“linker residue”) after one or more covalent bonds are formed) may still be referred to as a “linker” herein. The term “linker precursor” refers to a linker having one or more reactive groups capable of forming a covalent bond with a macromolecule, or compound or drug moiety, or both. A person of ordinary skill in the art, given the context of how the term linker is used, would understand whether “linker” means linker111107438300\1\AMERICASAttorney Docket No. 108843.00624precursor with one reactive group, a linker precursor with more than one reactive groups, a linker residue which is covalently bonded to the macromolecule, a linker residue which is covalently bonded to a compound or drug moiety, and / or a linker residue which is covalently bonded to the macromolecule and is covalently bonded to a compound or drug moiety. In some embodiments, the linker is a cleavable linker. For example, a cleavable linker can be one that is released by a bio-labile or enzymatic function, which may or may not be engineered. In some embodiments, the linker is a non-cleavable linker. For example, a non-cleavable linker can be one that is released upon degradation of the macromolecular moiety.
[0055] Percent “identity” between a polypeptide sequence and a reference sequence, is defined as the percentage of amino acid residues in the polypeptide sequence that are identical to the amino acid residues in the reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, MEGALIGN (DNASTAR), CLUSTALW, CLUSTAL OMEGA, or MUSCLE software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
[0056] A “conservative substitution” or a “conservative amino acid substitution,” refers to the substitution an amino acid with a chemically or functionally similar amino acid. Conservative substitution tables providing similar amino acids are well known in the art. Polypeptide sequences having such substitutions are known as “conservatively modified variants.” By way of example, the groups of amino acids provided in Tables 2-4 are, in some embodiments, considered conservative substitutions for one another.Table 2. Selected groups of amino acids that are considered conservative substitutions for one another, in certain embodiments.121107438300\1\AMERICASAttorney Docket No. 108843.00624Table 3. Additional selected groups of amino acids that are considered conservative substitutions for one another, in certain embodiments.Table 4. Further selected groups of amino acids that are considered conservative substitutions for one another, in certain embodiments.
[0057] Additional conservative substitutions may be found, for example, in Creighton, Proteins: Structures and Molecular Properties 2nd ed. (1993) W. H. Freeman & Co., New York, NY. An antibody generated by making one or more conservative substitutions of amino acid residues in a parent antibody is referred to as a “conservatively modified variant.”
[0058] The term “amino acid” refers to the twenty common naturally occurring amino acids. Naturally occurring amino acids include alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine (Cys; C); glutamic acid (Glu; E), glutamine (Gin; Q), Glycine (Gly; G); histidine (His; H), isoleucine (He; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Vai; V).
[0059] “Treating” or “treatment” of any disease or disorder refers, in certain embodiments, to ameliorating a disease or disorder that exists in a subject. In another embodiment, “treating” or “treatment” includes ameliorating at least one physical parameter, which may be indiscernible by the subject. In yet another embodiment, “treating” or “treatment” includes modulating the 131107438300\1\AMERICASAttorney Docket No. 108843.00624disease or disorder, either physically (e.g., stabilization of a discernible symptom) or physiologically e.g., stabilization of a physical parameter) or both. In yet another embodiment, “treating” or “treatment” includes delaying or preventing the onset of the disease or disorder.
[0060] As used herein, the term “therapeutically effective amount” or “effective amount” refers to an amount of an antibody or composition that when administered to a subject is effective to treat a disease or disorder.
[0061] As used herein, the term “subject” means a mammalian subject. Exemplary subjects include, but are not limited to humans, monkeys, dogs, cats, mice, rats, cows, horses, camels, avians, goats, and sheep. In certain embodiments, the subject is a human. In some embodiments, the subject has a disease that can be treated or diagnosed with an antibody provided herein. In some embodiments, the disease is gastric carcinoma, colorectal carcinoma, renal cell carcinoma, cervical carcinoma, non-small cell lung carcinoma, ovarian cancer, prostate cancer, and / or a cancer of epithelial origin.
[0062] The terms “non-natural amino acid,” (or “unnatural amino acid”) “synthetic amino acid,” or “modified amino acid” are a, b, g, or d amino acids, and includes but is not limited to, amino acids found in proteins, i.e., glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine. In certain embodiments, the amino acid is in the L-configuration. Alternatively, the amino acid can be a derivative of alanyl, valinyl, leucinyl, isoleucinyl, prolinyl, phenylalaninyl, tryptophanyl, methioninyl, glycinyl, serinyl, threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl, aspartoyl, glutaroyl, lysinyl, argininyl, histidinyl, b-alanyl, b-valinyl, b-leucinyl, b-isoleuccinyl, b-prolinyl, b-phenylalaninyl, b -tryptophanyl, b-methioninyl, b-glycinyl, b-serinyl, b-threoninyl, b-cysteinyl, b-tyrosinyl, b-asparaginyl, b-glutaminyl, b-aspartoyl, b-glutaroyl, b-lysinyl, b-argininyl or b-histidinyl. Unnatural amino acids are not proteinogenic amino acids, or post translationally modified variants thereof that either occur naturally or are chemically synthesized. In particular, the term unnatural amino acid refers to an amino acid that is not one of the 20 common amino acids or pyrrolysine or selenocysteine, or post translationally modified variants thereof. Non-limiting examples of unnatural amino acids include sulfoalanine, hydroxyproline (Hyp), beta-alanine, citrulline (Cit), ornithine (Orn), norleucine (Nle), 3 -nitrotyrosine, nitroarginine, pyroglutamic acid (Pyr), naphtylalanine (Nal), 2,4-diaminobutyric acid (DAB), methionine sulfoxide, and methionine sulfone.
[0063] The terms “non-natural amino acid,” (or “unnatural amino acid”) “synthetic amino acid,” or “modified amino acid” can also refer to an amino acid that comprises a reactive group141107438300\1\AMERICASAttorney Docket No. 108843.00624capable of forming a covalent bond to a linker payload. The reactive group can be an amino, carboxy, acetyl, hydrazino, hydrazido, hydroxylamine, semicarbazido, sulfanyl, azido or alkynyl group. Non-limiting examples of non-natural amino acids include p-acetyl-L-phenylalanine, O-methyl-L-tyrosine, 3-methyl-phenylalanine, O-4-allyl-L-tyrosine, 4-propyl-L-tyrosine, fluorinated phenylalanine, isopropyl-L-phenylalanine, p-azido-L-phenylalanine, p-acyl-L-phenylalanine, p-benzoyl-L-phenylalanine, p-iodo-phenylalanine, p-bromophenylalanine, p-amino-L-phenylalanine, isopropyl-L-phenylalanine, p-propargyloxy-phenylalanine, and p-azidomethyl-L-phenyl alanine.
[0064] “pAMF” or “pAzMeF” mutation refers to a variant phenylalanine residue, / .<?., para-azidomethyl-L-phenylalanine, added or substituted into a polypeptide.
[0065] “pAcF,” “pAcF residue,” or “pAcF mutation” refer to a variant phenylalanine residue, (i.e., para-acetyl-L-phenylalanine) added or substituted into a polypeptide.
[0066] “pAzF” mutation refers to a variant phenylalanine residue, (i.e., para-azido-L-phenylalanine) added or substituted into a polypeptide.2. ANTIBODIES
[0067] Provided herein are antibodies that selectively bind avP6. In some aspects, the antibodies selectively bind to human avP6. In some aspects, the antibodies selectively bind to the extracellular domain of human avP6.
[0068] In some embodiments, the antibody comprises three heavy chain CDRs from a VH sequence selected from SEQ ID NOs: 1244-1491, or variants thereof, and three light chain CDRs from a VL sequence selected from SEQ ID NOs: 4702-5167, or variants thereof. In some embodiments, the antibody comprises three heavy chain CDRs from a VH sequence selected from SEQ ID NOs: 1244-1491, or variants thereof, and three light chain CDRs from a VL sequence set forth in SEQ ID NO: 1495, or variants thereof.
[0069] In some embodiments, the antibody comprises three heavy chain CDRs from a heavy chain sequence selected from SEQ ID NOs: 1497-1511, or variants thereof, and three light chain CDRs from a light chain sequence set forth in SEQ ID NOs: 1496, or variants thereof.
[0070] In some embodiments, the antibody binds to a homolog of human avP6. In some aspects, the antibody binds to a homolog of human avP6 from a species selected from monkeys, mice, dogs, cats, rats, cows, horses, goats, and sheep. In some aspects, the homolog is a cynomolgus monkey homolog. In some aspects, the homolog is a mouse or murine analog.
[0071] In some embodiments, the antibody comprises a light chain. In some aspects, the light chain is a kappa light chain. In some aspects, the light chain is a lambda light chain.151107438300\1\AMERICASAttorney Docket No. 108843.00624
[0072] In some embodiments, the antibody comprises a heavy chain. In some aspects, the heavy chain is an IgA. In some aspects, the heavy chain is an IgD. In some aspects, the heavy chain is an IgE. In some aspects, the heavy chain is an IgG. In some aspects, the heavy chain is an IgM. In some aspects, the heavy chain is an IgGl. In some aspects, the heavy chain is an IgG2. In some aspects, the heavy chain is an IgG3. In some aspects, the heavy chain is an IgG4. In some aspects, the heavy chain is an IgAl. In some aspects, the heavy chain is an IgA2.
[0073] In some embodiments, the antibody is an antibody fragment. In some aspects, the antibody fragment is an Fv fragment. In some aspects, the antibody fragment is a Fab fragment. In some aspects, the antibody fragment is a F(ab’)2 fragment. In some aspects, the antibody fragment is a Fab’ fragment. In some aspects, the antibody fragment is an scFv (sFv) fragment. In some aspects, the antibody fragment is an scFv-Fc fragment. In some aspects, the antibody fragment is a single chain Fab (e.g., comprising VLCL-VH) fragment.
[0074] In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a polyclonal antibody.
[0075] In some embodiments, the antibody is a chimeric antibody. In some embodiments, the antibody is a humanized antibody. In some embodiments, the antibody is a human antibody.
[0076] In some embodiments, the antibody is an affinity matured antibody. In some aspects, the antibody is an affinity matured antibody derived from an illustrative sequence provided in this disclosure.
[0077] The antibodies provided herein may be useful for the treatment of a variety of diseases and conditions including cancers. In some embodiments, the antibodies provided herein may be useful for the treatment of cancers of solid tumors. For example, the antibodies provided herein can be useful for the treatment of colorectal cancer.2.1. Kabat CDR-H1 + Kabat CDR-H2 + Kabat CDR-H3
[0078] In some embodiments, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of, a sequence selected from SEQ ID NOs: 4-251, a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of, a sequence selected from SEQ ID NOs: 500-747, and a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of, a sequence selected from SEQ ID NOs: 996-1243. In some aspects, the Kabat CDR-H1 sequence, Kabat CDR-H2 sequence, and Kabat CDR-H3 sequence are all from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Kabat CDR-H1, Kabat CDR-H2, and Kabat CDR-H3 are all from a single illustrative VH sequence selected from SEQ ID NOs: 1244-1491.161107438300\1\AMERICASAttorney Docket No. 108843.00624
[0079] In some embodiments, the antibody comprises a Kabat CDR-H1 sequence, a Kabat CDR-H2 sequence, and a Kabat CDR-H3 sequence each having the same Molecule ID in Table 16
[0080] In some embodiments, the antibody comprises three Kabat HC CDRs selected from the group consisting of SEQ ID NOs: 133 / 629 / 1125, 166 / 662 / 1158, 167 / 663 / 1159, 168 / 664 / 1160, 184 / 680 / 1176, 224 / 720 / 1216, 234 / 730 / 1226, 247 / 743 / 1239, 248 / 744 / 1240, and 249 / 745 / 1241, 251 / 747 / 1243.2.2. Variants of VH Sequences Comprising Illustrative Kabat CDRs
[0081] In some embodiments, the VH sequences provided herein comprise a variant of an illustrative Kabat CDR-H3, CDR-H2, and / or CDR-H1 sequence provided in this disclosure.
[0082] In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-H3 sequence provided in this disclosure. In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Kabat CDR-H3 sequences provided in this disclosure. In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0083] In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-H2 sequence provided in this disclosure. In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Kabat CDR-H2 sequences provided in this disclosure. In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-H2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0084] In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-H1 sequence provided in this disclosure. In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Kabat CDR-H1 sequences provided in this disclosure. In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of any of the171107438300\1\AMERICASAttorney Docket No. 108843.00624illustrative Kabat CDR-H1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.2.3. Chothia CDR-H1 + Chothia CDR-H2 + Chothia CDR-H3
[0085] In some embodiments, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of, a sequence selected from SEQ ID NOs: 252-499, a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of, a sequence selected from SEQ ID NOs: 748-995, and a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of, a sequence selected from SEQ ID NOs: 996-1243. In some aspects, the Chothia CDR-H1 sequence, Chothia CDR-H2 sequence, and Chothia CDR-H3 sequence are all from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Chothia CDR-H1, Chothia CDR-H2, and Chothia CDR-H3 are all from a single illustrative VH sequence selected from SEQ ID NOs: 1244-1491.
[0086] In some embodiments, the antibody comprises a Chothia CDR-H1 sequence, a Chothia CDR-H2 sequence, and a Chothia CDR-H3 sequence each having the same Molecule ID in Table 16
[0087] In some embodiments, the isolated antibody comprises three Chothia HC CDRs selected from the group consisting of SEQ ID NOs: 381 / 877 / 1125 / 1492 / 1493 / 1494; 414 / 910 / 1158 / 1492 / 1493 / 1494; 415 / 911 / 1159 / 1492 / 1493 / 1494; 416 / 912 / 1160 / 1492 / 1493 / 1494; 432 / 928 / 1176 / 1492 / 1493 / 1494; 472 / 968 / 1216 / 1492 / 1493 / 1494; 482 / 978 / 1226 / 1492 / 1493 / 1494; 495 / 991 / 1239 / 1492 / 1493 / 1494; 496 / 992 / 1240 / 1492 / 1493 / 1494; 497 / 993 / 1241 / 1492 / 1493 / 1494; and 499 / 995 / 1243 / 1492 / 1493 / 1494.2.4. Variants of VH Sequences Comprising Illustrative Chothia CDRs
[0088] In some embodiments, the VH sequences provided herein comprise a variant of an illustrative Chothia CDR-H3, CDR-H2, and / or CDR-H1 sequence provided in this disclosure.
[0089] In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-H3 sequence provided in this disclosure. In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Chothia CDR-H3 sequences provided in this disclosure. In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino181107438300\1\AMERICASAttorney Docket No. 108843.00624acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0090] In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-H2 sequence provided in this disclosure. In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Chothia CDR-H2 sequences provided in this disclosure. In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-H2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0091] In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-H1 sequence provided in this disclosure. In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Chothia CDR-H1 sequences provided in this disclosure. In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-H1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.2.5. VH Sequences
[0092] In some embodiments, the antibody comprises, consists of, or consists essentially of a VH sequence provided in SEQ ID NOs: 1244-1491. In some embodiments, the antibody comprises, consists of, or consists essentially of a VH sequence provided in SEQ ID NOs: 1373, 1406, 1407, 1408, 1424, 1464, 1474, 1487, 1488, 1489, and 1491.
[0093] In some embodiments, the antibody comprises a CDR-H3, a CDR-H2, and a CDR-Hl, each consisting of a CDR sequence of a VH having the sequence set forth in one of SEQ ID NOS: 1244-1491. In some embodiments, the antibody comprises a CDR-H3, a CDR-H2, a CDR-H1, and framework regions, each consisting of a CDR sequence or framework sequence of a VH having the sequence set forth in one of SEQ ID NOs: 1244-1491.
[0094] In some embodiments, the antibody comprises a CDR-H3, a CDR-H2, and a CDR-Hl, each consisting of a CDR sequence of a VH having the sequence set forth in one of SEQ ID NOS: 1373, 1406, 1407, 1408, 1424, 1464, 1474, 1487, 1488, 1489, and 1491. In some embodiments, the antibody comprises a CDR-H3, a CDR-H2, a CDR-H1, and framework191107438300\1\AMERICASAttorney Docket No. 108843.00624regions, each consisting of a CDR sequence or framework sequence of a VH having the sequence set forth in one of SEQ ID NOS: 1373, 1406, 1407, 1408, 1424, 1464, 1474, 1487, 1488, 1489, and 1491.2.6. Variants of VH Sequences
[0095] In some embodiments, the VH sequences provided herein comprise, consist of, or consist essentially of a variant of an illustrative VH sequence provided in this disclosure.
[0096] In some aspects, the VH sequence comprises, consists of, or consists essentially of a variant of an illustrative VH sequence provided in this disclosure. In some aspects, the VH sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative VH sequences provided in this disclosure.
[0097] In some embodiments, the VH sequence comprises, consists of, or consists essentially of any of the illustrative VH sequences provided in this disclosure having 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.2.7. CDR-L1 + CDR-L2 + CDR-L3
[0098] In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of, a sequence set forth in SEQ ID NO: 1492, a CDR-L2 sequence comprising, consisting of, or consisting essentially of, a sequence set forth in SEQ ID NO: 1493, and a CDR-L3 sequence comprising, consisting of, or consisting essentially of, a sequence set forth in SEQ ID NO: 1494. In some aspects, the CDR-L1 sequence, CDR-L2 sequence, and CDR-L3 sequence are all from a single illustrative VL sequence provided in this disclosure. For example, in some aspects, the CDR-L1, CDR-L2, and CDR-L3 are all from a single illustrative VL sequence set forth in SEQ ID NO: 1495.
[0099] In some embodiments, the antibody comprises a CDR-L1 sequence, a CDR-L2 sequence, and a CDR-L3 sequence each having the same Molecule ID in Table 16.
[0100] In some embodiments, the antibody comprises three LC CDRs set forth in SEQ ID NOs: 1492 / 1493 / 1494.2.8. Variants of VL Sequences Comprising Illustrative CDR-Ls
[0101] In some embodiments, the VL sequences provided herein comprise a variant of an illustrative CDR-L3, CDR-L2, and / or CDR-L1 sequence provided in this disclosure.201107438300\1\AMERICASAttorney Docket No. 108843.00624
[0102] In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L3 sequence provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative CDR-L3 sequences provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0103] In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L2 sequence provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative CDR-L2 sequences provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0104] In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L1 sequence provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative CDR-L1 sequences provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.2.9. VL Sequences
[0105] In some embodiments, the antibody comprises, consists of, or consists essentially of a VL sequence set forth in SEQ ID NO: 1495.
[0106] In some embodiments, the antibody comprises a CDR-L3, a CDR-L2, and a CDR-Ll, each consisting of a CDR sequence of a VL having the sequence set forth in SEQ ID NO: 1495. In some embodiments, the antibody comprises a CDR-L3, a CDR-L2, a CDR-L1, and framework regions, each consisting of a CDR sequence or framework sequence of a VL having the sequence set forth in SEQ ID NO: 1495.2.10. Variants of VL Sequences211107438300\1\AMERICASAttorney Docket No. 108843.00624
[0107] In some embodiments, the VL sequences provided herein comprise, consist of, or consist essentially of a variant of an illustrative VL sequence provided in this disclosure.
[0108] In some aspects, the VL sequence comprises, consists of, or consists essentially of a variant of an illustrative VL sequence provided in this disclosure. In some aspects, the VL sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative VL sequences provided in this disclosure.
[0109] In some embodiments, the VL sequence comprises, consists of, or consists essentially of any of the illustrative VL sequences provided in this disclosure having 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.2.11. VH - VL Pairs
[0110] In some embodiments, the antibody comprises a VH sequence and a VL sequence. In some aspects, the VH sequence is a VH sequence comprising, consisting of, or consisting essentially of, any one of SEQ ID NOs: 1244-1491, and the VL sequence is a VL sequence comprising, consisting of, or consisting essentially of, the sequence set forth in SEQ ID NO: 1495.
[0111] In some embodiments, the antibody comprises a VH sequence and a VL sequence each having the same Molecule ID in Table 16.
[0112] In some embodiments, the antibody comprises a VH - VL pair selected from SEQ ID NOs: 1373 / 1495, 1406 / 1495, 1407 / 1495, 1408 / 1495, 1424 / 1495, 1464 / 1495, 1474 / 1495, 1487 / 1495, 1488 / 1495, 1489 / 1495, and 1491 / 1495.2.12. Variants of VH - VL Pairs
[0113] In some embodiments, the VH - VL pairs provided herein comprise a variant of an illustrative VH and / or VL sequence provided in this disclosure. In some aspects, the VH sequence comprises, consists of, or consists essentially of a variant of an illustrative VH sequence provided in this disclosure. In some aspects, the VH sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative VH sequences provided in this disclosure.
[0114] In some embodiments, the VH sequence comprises, consists of, or consists essentially of any of the illustrative VH sequences provided in this disclosure having 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer,221107438300\1\AMERICASAttorney Docket No. 108843.0062411 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0115] In some aspects, the VL sequence comprises, consists of, or consists essentially of a variant of an illustrative VL sequence provided in this disclosure. In some aspects, the VL sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative VL sequences provided in this disclosure.
[0116] In some embodiments, the VL sequence comprises, consists of, or consists essentially of any of the illustrative VL sequences provided in this disclosure having 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.2.13. Heavy Chain - Light Chain Pairs
[0117] In some embodiments, the antibody comprises a heavy chain sequence of an antibody disclosed herein and a light chain sequence of a suitable antibody. In some embodiments, the antibody comprises a heavy chain sequence of an antibody disclosed herein and a light chain sequence of an antibody disclosed herein.
[0118] In some embodiments, the heavy chain comprises a VH sequence comprising, consisting of, or consisting essentially of, any one of SEQ ID NOs: 1244-1491, and the light chain comprises a light chain sequence of any suitable antibody. In some embodiments, the heavy chain comprises a VH sequence comprising, consisting of, or consisting essentially of, any one of SEQ ID NOs: 1244-1491, and the light chain comprises a VL sequence comprising, consisting of, or consisting essentially of, the sequence set forth in SEQ ID NO: 1495. Techniques for determining whether a particular light chain will pair with a heavy chain as described herein are well known to those of skill in the art. For example, a cell-free protein synthesis reaction comprising a nucleic acid encoding the heavy chain of interest and a nucleic acid encoding the light chain to be assessed may be performed as described.
[0119] In some embodiments, the heavy chain comprises, consists of, or consists essentially of, any one of SEQ ID NOs: 1497-1511, and the light chain comprises a light chain sequence of any suitable antibody. In some embodiments, the heavy chain comprises, consists of, or consists essentially of, any one of SEQ ID NOs: 1497-1511, and the light chain comprises, consists of, or consists essentially of, the sequence set forth SEQ ID NO: 1496. For example, the Techniques231107438300\1\AMERICASAttorney Docket No. 108843.00624for determining whether a particular light chain will pair with a heavy chain as described herein are well known to those of skill in the art. For example, a cell-free protein synthesis reaction comprising a nucleic acid encoding the heavy chain of interest and a nucleic acid encoding the light chain to be assessed may be performed as described.2.13. Variants of heavy chain - light chain Pairs
[0120] In some embodiments, the heavy chain-light chain pairs provided herein comprise a variant of an illustrative heavy chain and / or light chain sequence provided in this disclosure. In some aspects, the heavy chain sequence comprises, consists of, or consists essentially of a variant of an illustrative heavy chain sequence provided in this disclosure. In some aspects, the heavy chain sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative heavy chain sequences provided in this disclosure.
[0121] In some embodiments, the heavy chain sequence comprises, consists of, or consists essentially of any of the illustrative heavy chain sequences provided in this disclosure having 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0122] In some aspects, the light chain sequence comprises, consists of, or consists essentially of a variant of an illustrative light chain sequence provided in this disclosure. In some aspects, the light chain sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative light chain sequences provided in this disclosure.
[0123] In some embodiments, the light chain sequence comprises, consists of, or consists essentially of any of the illustrative light chain sequences provided in this disclosure having 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.2.15. Antibodies Comprising All Six CDRs
[0124] In some embodiments, the antibody comprises a CDR-H1 sequence, a CDR-H2 sequence, a CDR-H3 sequence, a CDR-L1 sequence, and a CDR-L3 sequence. In some aspects, the CDR sequences are part of a VH (for CDR-H) or VL (for CDR-L).241107438300\1\AMERICASAttorney Docket No. 108843.00624
[0125] In some embodiments, the antibody comprises a CDR-H3, a CDR-H2, CDR-H1, a CDR-L3, a CDR-L2, and a CDR-L1 of a VH - VL pair selected from the group consisting of SEQ ID NOS: 1373 / 1495, 1406 / 1495, 1407 / 1495, 1408 / 1495, 1424 / 1495, 1464 / 1495, 1474 / 1495, 1487 / 1495, 1488 / 1495, 1489 / 1495, and 1491 / 1495.
[0126] In some aspects, the CDR-H1 sequence is a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of, any one of SEQ ID NOs: 252-499; the CDR-H2 sequence is a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of, any one of SEQ ID NOs: 748-995; the CDR-H3 sequence is a CDR-H3 sequence comprising, consisting of, or consisting essentially of, any one of SEQ ID NOs: 996-1243; the CDR-L1 sequence is a CDR-L1 sequence comprising, consisting of, or consisting essentially of, SEQ ID NO: 1492; the CDR-L2 sequence is a CDR-L2 sequence comprising, consisting of, or consisting essentially of, SEQ ID NO: 1493; and the CDR-L3 sequence is a CDR-L3 sequence comprising, consisting of, or consisting essentially of, SEQ ID NO: 1494.
[0127] In some aspects, the CDR-H1 sequence is a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of, any one of SEQ ID NOs: 4-251; the CDR-H2 sequence is a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of, any one of SEQ ID NOs: 500-747; the CDR-H3 sequence is a CDR-H3 sequence comprising, consisting of, or consisting essentially of, any one of SEQ ID NOs: 996-1243; the CDR-L1 sequence is a CDR-L1 sequence comprising, consisting of, or consisting essentially of, SEQ ID NO: 1492; the CDR-L2 sequence is a CDR-L2 sequence comprising, consisting of, or consisting essentially of, SEQ ID NO: 1493; and the CDR-L3 sequence is a CDR-L3 sequence comprising, consisting of, or consisting essentially of, SEQ ID NO: 1494.
[0128] In some embodiments, the antibody comprises a Kabat CDR-H1, a Kabat CDR-H2, a CDR-H3, each of which has the same Molecule ID in Table 16, and a CDR-L1, a CDR-L2, and a CDR-L3 of Trastuzumab in Table 16.
[0129] In some embodiments, the antibody comprises six CDRs selected from the group consisting of SEQ ID NOs: 133 / 629 / 1125 / 1492 / 1493 / 1494, 166 / 662 / 1158 / 1492 / 1493 / 1494, 167 / 663 / 1159 / 1492 / 1493 / 1494, 168 / 664 / 1160 / 1492 / 1493 / 1494, 184 / 680 / 1176 / 1492 / 1493 / 1494, 224 / 720 / 1216 / 1492 / 1493 / 1494, 234 / 730 / 1226 / 1492 / 1493 / 1494, 247 / 743 / 1239 / 1492 / 1493 / 1494, 248 / 744 / 1240 / 1492 / 1493 / 1494, 249 / 745 / 1241 / 1492 / 1493 / 1494, and251 / 747 / 1243 / 1492 / 1493 / 1494.251107438300\1\AMERICASAttorney Docket No. 108843.00624
[0130] In some embodiments, the antibody comprises a Chothia CDR-H1, a Kabat CDR-H2, a CDR-H3, each of which has the same Molecule ID in Table 16, and a CDR-L1, a CDR-L2, and a CDR-L3 of Trastuzumab in Table 16.
[0131] In some embodiments, the antibody comprises six CDRs selected from the group consisting of SEQ ID NOs: 381 / 877 / 1125 / 1492 / 1493 / 1494; 414 / 910 / 1158 / 1492 / 1493 / 1494; 415 / 911 / 1159 / 1492 / 1493 / 1494; 416 / 912 / 1160 / 1492 / 1493 / 1494;432 / 928 / 1176 / 1492 / 1493 / 1494; 472 / 968 / 1216 / 1492 / 1493 / 1494;482 / 978 / 1226 / 1492 / 1493 / 1494; 495 / 991 / 1239 / 1492 / 1493 / 1494;496 / 992 / 1240 / 1492 / 1493 / 1494; 497 / 993 / 1241 / 1492 / 1493 / 1494; and 499 / 995 / 1243 / 1492 / 1493 / 1494.2.16. Variants of Antibodies Comprising All Six CDRs
[0132] In some embodiments, the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 provided herein comprise a variant of an illustrative CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and / or CDR-L3 sequence provided in this disclosure.
[0133] In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia or Kabat CDR-H1 sequence provided in this disclosure. In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Chothia or Kabat CDR-H1 sequences provided in this disclosure. In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia or Kabat CDR-H1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0134] In some aspects, the CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia or Kabat CDR-H2 sequence provided in this disclosure. In some aspects, the CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Chothia or Kabat CDR-H2 sequences provided in this disclosure. In some aspects, the CDR-H2 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia or Kabat CDR-H2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0135] In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-H3 sequence provided in this disclosure. In some aspects, the261107438300\1\AMERICASAttorney Docket No. 108843.00624CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative CDR-H3 sequences provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0136] In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L1 sequence provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative CDR-L1 sequences provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0137] In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L2 sequence provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative CDR-L2 sequences provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
[0138] In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L3 sequence provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative CDR-L3 sequences provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.2.17. Constant Region Sequences
[0139] In some embodiments, the antibody of any one of the preceding embodiments comprises at least one constant region domain.271107438300\1\AMERICASAttorney Docket No. 108843.00624
[0140] In some embodiments, the antibody, of any one of the preceding embodiments, comprises a constant region in a heavy chain sequence set forth in one of SEQ ID NOS: 1497-1511. In some embodiments, the antibody, of any one of the preceding embodiments, comprises a constant region in a light chain sequence set forth in SEQ ID NO: 1496. In some embodiments, the antibody, of any one of the preceding embodiments, comprises a constant region in a heavy chain sequence set forth in one of SEQ ID NOS: 1497-1511 and in a light chain sequence set forth in SEQ ID NO: 1496.2.18. Framework Regions
[0141] In some embodiments, the antibody of any of the previous embodiments further comprises human framework regions.
[0142] In some embodiments, the antibody of any of the previous embodiments, further comprises human kappa framework regions.
[0143] In some embodiments, the antibody comprises one or more frameworks in of a VH sequence selected from SEQ ID NOS: 1244-1491. In some embodiments, the antibody comprises one or more frameworks in of a VH sequence selected from SEQ ID NOS: 1373, 1406, 1407, 1408, 1424, 1464, 1474, 1487, 1488, 1489, and 1491.
[0144] In some embodiments, the antibody comprises one or more frameworks in of a VL sequence set forth in SEQ ID NO: 1495.4. GERMLINE
[0145] One of skill in the art would recognize that the CDR sequences provided herein may also be useful when combined with variable regions encoded by other variable region germline genes, or variants thereof. In particular, the CDR sequences provided herein may be useful when combined with variable regions encoded by variable region germline genes, or variants thereof, that are structurally similar to the variable region germline genes recited above. For example, in some embodiments, a CDR-H sequence provided herein may be combined with a variable region encoded by a variable region germline gene selected from the VH 1, VH 2, VH 3, or VH 4 families, or a variant thereof. In some embodiments, a CDR-L sequence provided herein may be combined with a variable region encoded by a variable region germline gene selected from the VKI, VK2, or VK3, or a variant thereof.5. AFFINITY
[0146] In some embodiments, the affinity of the antibody for avP6 as indicated by KD, is less than about 10'5M, less than about 10'6M, less than about 10'7M, less than about 10'8M, less than about 10'9M, less than about IO'10M, less than about 10'11M, less than about 10'12M.281107438300\1\AMERICASAttorney Docket No. 108843.00624In some embodiments, the affinity of the antibody is between about 10'6M and about 10'12M. In some embodiments, the affinity of the antibody is between about 10'7M and about 10'12M. In some embodiments, the affinity of the antibody is between about 10'7M and about 10'11M. In some embodiments, the affinity of the antibody is between about 10'7M and about IO'10M. In some embodiments, the affinity of the antibody is between about 10'7M and about 10'9M. In some embodiments, the affinity of the antibody is between about 10'7M and about 10'8M. In some embodiments, the affinity of the antibody is between about 10'8M and about 10'12M. In some embodiments, the affinity of the antibody is between about 10'8M and about 10'11M. In some embodiments, the affinity of the antibody is between about 10'8M and about IO'10M. In some embodiments, the affinity of the antibody is between about 10'8M and about 10'9M. In some embodiments, the affinity of the antibody is between about 10'9M and about 10'12M. In some embodiments, the affinity of the antibody is between about 10'9M and about 10'11M. In some embodiments, the affinity of the antibody is between about 10'9M and about IO'10M. In some embodiments, the affinity of the antibody is between about IO'10M and about 10'12M. In some embodiments, the affinity of the antibody is between about 10'11M and about 10'12M.
[0147] In some embodiments the antibody has a kaof at least about 103M^xsec’1. In some embodiments the antibody has a kaof at least about 104M^xsec’1. In some embodiments the antibody has a kaof at least about 105M^xsec'1. In some embodiments the antibody has a kaof at least about 106M^xsec'1. In some embodiments the antibody has a kaof between about 103M^xsec'1and about 107M^xsec'1. In some embodiments the antibody has a kaof between about 103M^xsec'1and about 104M^xsec'1. In some embodiments the antibody has a kaof between about 103M^xsec'1and about 105M^xsec'1. In some embodiments the antibody has a kaof between about 103M'^sec'1and about 106M^xsec'1. In some embodiments the antibody has a kaof between about 104M'^sec'1and about 105M^xsec'1. In some embodiments the antibody has a kaof between about 104M'^sec'1and about 106M^xsec'1. In some embodiments the antibody has a kaof between about 104M'^sec'1and about 107M^xsec'1. In some embodiments the antibody has a kaof between about 105M'^sec'1and about 106M^xsec'1. In some embodiments the antibody has a kaof between about 105M'^sec'1and about 107M^xsec'1. In some embodiments the antibody has a kaof between about 106M'^sec'1and about 107M'^sec'1
[0148] In some embodiments the antibody has a ka of about 10'8sec'1or less. In some embodiments the antibody has a ka of about 10'7sec'1or less. In some embodiments the antibody has a ka of about 10'6sec'1or less. In some embodiments the antibody has a ka of about 10'5sec'1or less. In some embodiments the antibody has a ka of about 10'4sec'1or less. In some291107438300\1\AMERICASAttorney Docket No. 108843.00624embodiments the antibody has a ka of about 10'3sec'1or less. In some embodiments the antibody has a ka of between about 10'2sec'1and about 10'8sec'1. In some embodiments the antibody has a ka of between about 10'2sec'1and about 10'7sec'1. In some embodiments the antibody has a ka of between about 10'2sec'1and about 10'6sec'1. In some embodiments the antibody has a ka of between about 10'2sec'1and about 10'5sec'1. In some embodiments the antibody has a ka of between about 10'2sec'1and about 10'4sec'1. In some embodiments the antibody has a ka of between about 10'2sec'1and about 10'3sec'1. In some embodiments the antibody has a ka of between about 10'3sec'1and about 10'8sec'1. In some embodiments the antibody has a ka of between about 10'3sec'1and about 10'7sec'1. In some embodiments the antibody has a ka of between about 10'3sec'1and about 10'6sec'1. In some embodiments the antibody has a ka of between about 10'3sec'1and about 10'5sec'1. In some embodiments the antibody has a ka of between about 10'3sec'1and about 10'4sec'1. In some embodiments the antibody has a ka of between about 10'4sec'1and about 10'8sec'1. In some embodiments the antibody has a ka of between about 10'4sec'1and about 10'7sec'1. In some embodiments the antibody has a ka of between about 10'4sec'1and about 10'6sec'1. In some embodiments the antibody has a ka of between about 10'4sec'1and about 10'5sec'1. In some embodiments the antibody has a ka of between about 10'5sec'1and about 10'8sec'1. In some embodiments the antibody has a ka of between about 10'5sec'1and about 107sec'1. In some embodiments the antibody has a ka of between about 10'5sec'1and about 10'6sec'1. In some embodiments the antibody has a ka of between about 10'6sec'1and about 10'8sec'1. In some embodiments the antibody has a ka of between about 10'6sec'1and about 10'7sec'1. In some embodiments the antibody has a ka of between about 10'7sec'1and about 10'8sec'1.
[0149] In some embodiments, the affinity of the antibody for human avP6, human avP6 extracellular domain, or for individual domains within human avP6, as determined by surface plasmon resonance at 25°C, and as indicated by KD, is from 4 xlO'9M to 10 xlO'8M, e.g., from 4.1 xlO'9M to 10 xlO'8M, from 4.1 xlO'9M to 5.3 xlO'9M, or from 4.1 xlO'9M to 5.2 xlO'9M. In some embodiments, the affinity of the antibody for human avP6 is about any of the KD values reported for human avP6 in the examples below.
[0150] In some aspects, the KD, ka, and ka are determined at 25°C. In some embodiments, the KD, ka, and ka are determined by surface plasmon resonance. In some embodiments, the KD, ka, and ka are determined according to the methods described in the Examples provided herein.301107438300\1\AMERICASAttorney Docket No. 108843.006246. EPITOPE BINS
[0151] In some embodiments, the antibody binds the same epitope as an antibody comprising any of the VH-VL pairs, above. In some embodiments, the antibody competes for epitope binding with an antibody comprising any of the VH-VL pairs, above.
[0152] In some embodiments, the antibody specifically binds to avP6, wherein the antibody binds to the same epitope as, substantially the same epitope as, an epitope that overlaps with, or an epitope that substantially overlaps with, the epitope of, a second antibody comprising a VH region selected from any one of SEQ ID NOs: 1244 -1491, and a VL region set forth in SEQ ID NO: 1495. In some embodiments, the antibodies bind the same epitope as the epitope of an antibody comprising a VH region set forth in SEQ ID NO: 1373, and a VL region set forth in SEQ ID NO: 1495. In some embodiments, the antibodies bind to the same epitope as the epitope of an antibody comprising a VH region set forth in SEQ ID NO: 1487, and a VL region set forth in SEQ ID NO: 1495.7. GLYCOSYLATION VARIANTS
[0153] In certain embodiments, an antibody may be altered to increase, decrease or eliminate the extent to which it is glycosylated. In certain embodiments, an antibody may be altered to be aglycosylated. Glycosylation of polypeptides is typically either “N-linked” or “O-linked.”
[0154] “N-linked” glycosylation refers to the attachment of a carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site.
[0155] “O-linked” glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.
[0156] Addition or deletion of N-linked glycosylation sites to the antibody may be accomplished by altering the amino acid sequence such that one or more of the above-described tripeptide sequences is created or removed. Addition or deletion of O-linked glycosylation sites may be accomplished by addition, deletion, or substitution of one or more serine or threonine residues in or to (as the case may be) the sequence of an antibody.311107438300\1\AMERICASAttorney Docket No. 108843.006248. Fc VARIANTS
[0157] In certain embodiments, amino acid modifications may be introduced into the Fc region of an antibody provided herein to generate an Fc region variant. In certain embodiments, the Fc region variant possesses some, but not all, effector functions. Such antibodies may be useful, for example, in applications in which the half-life of the antibody in vivo is important, yet certain effector functions are unnecessary or deleterious. Examples of effector functions include complement-dependent cytotoxicity (CDC) and antibody-directed complement-mediated cytotoxicity (ADCC). Numerous substitutions or substitutions or deletions with altered effector function are known in the art.
[0158] An alteration in CDC and / or ADCC activity can be confirmed using in vitro and / or in vivo assays. For example, Fc receptor (FcR) binding assays can be conducted to measure FcyR binding. The primary cells for mediating ADCC, NK cells, express FcyRIII only, whereas monocytes express FcyRI, FcyRII and FcyRIII. FcR expression on hematopoietic cells is summarized in Ravetch and Kinet, Ann. Rev. Immunol., 1991, 9:457-492, incorporated by reference in its entirety.
[0159] Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest are provided in U. S. Patent NOs 5,500,362 and 5,821,337; Hellstrom et al., Proc. Natl. Acad. Sci. U. S. A., 1986, 83:7059-7063; Hellstrom et al., Proc. Natl. Acad. Sci. U. S. A., 1985, 82:1499-1502; and Bruggemann et al., J. Exp. Med., 1987, 166:1351-1361; each of which is incorporated by reference in its entirety. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, using an animal model such as that disclosed in Clynes et al. Proc. Natl. Acad. Sci. U. S. A., 1998, 95:652-656, incorporated by reference in its entirety.
[0160] Clq binding assays may also be carried out to confirm that the antibody is unable to bind Clq and hence lacks CDC activity. Examples of Clq binding assays include those described in WO 2006 / 029879 and WO 2005 / 100402, each of which is incorporated by reference in its entirety.
[0161] Complement activation assays include those described, for example, in Gazzano-Santoro et al., J. Immunol. Methods, 1996, 202:163-171; Cragg et al., Blood, 2003, 101:1045- 1052; and Cragg and Glennie, Blood, 2004, 103:2738-2743; each of which is incorporated by reference in its entirety.321107438300\1\AMERICASAttorney Docket No. 108843.00624
[0162] FcRn binding and in vivo clearance (half-life determination) can also be measured, for example, using the methods described in Petkova et al., Inti. Immunol., 2006, 18: 1759-1769, incorporated by reference in its entirety.
[0163] In some embodiments, the antibodies provided herein comprise one or more amino acid substitutions that confer improved effects (e.g. thermal stability, improved antibody yields, improved antibody titers) as described in PCT Application WO 2017 / 218698, which is incorporated by reference in its entirety. In some embodiments, the antibody comprises one or more amino acid substitutions in the CH2 domain of the heavy chain. In some embodiments, the one or more amino acid substitutions is at V262, V264, V303, or V305. In some embodiments, the one or more amino acid substitutions is V262E, V262D, V262K, V262R, V262S, V264S, V303R, V305R, or a combination thereof. In some embodiments, the antibody comprises an amino acid substitution at V264. In one example, the antibody comprises an amino acid substitution V264S.9. PREPARATION OF ANTIBODIES9.1. Antigen Preparation
[0164] The avP6 protein to be used for isolation of the antibodies may be intact avP6 or a fragment of avP6. The intact avP6 protein, or fragment of avP6, may be in the form of an isolated protein or protein expressed by a cell. Other forms of avP6 useful for generating antibodies will be apparent to those skilled in the art.9.2. Monoclonal Antibodies
[0165] Monoclonal antibodies may be obtained, for example, using the hybridoma method first described by Kohler et al., Nature, 1975, 256:495-497 (incorporated by reference in its entirety), and / or by recombinant DNA methods (see e.g., U. S. Patent No. 4,816,567, incorporated by reference in its entirety). Monoclonal antibodies may also be obtained, for example, using phage or yeast-based libraries. See e.g., U. S. Patent NOs 8,258,082 and 8,691,730, each of which is incorporated by reference in its entirety.
[0166] In the hybridoma method, a mouse or other appropriate host animal is immunized to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized in vitro. Lymphocytes are then fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell. See Goding J. W., Monoclonal Antibodies: Principles and Practice 3rded. (1986) Academic Press, San Diego, CA, incorporated by reference in its entirety.331107438300\1\AMERICASAttorney Docket No. 108843.00624
[0167] The hybridoma cells are seeded and grown in a suitable culture medium that contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT -deficient cells.
[0168] Useful myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive media conditions, such as the presence or absence of HAT medium. Among these, preferred myeloma cell lines are murine myeloma lines, such as those derived from MOP -21 and MC-11 mouse tumors (available from the Salk Institute Cell Distribution Center, San Diego, CA), and SP-2 or X63-Ag8-653 cells (available from the American Type Culture Collection, Rockville, MD). Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies. See e.g., Kozbor, J. Immunol., 1984, 133:3001, incorporated by reference in its entirety.
[0169] After the identification of hybridoma cells that produce antibodies of the desired specificity, affinity, and / or biological activity, selected clones may be subcloned by limiting dilution procedures and grown by standard methods. See Goding, supra. Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown in vivo as ascites tumors in an animal.
[0170] DNA encoding monoclonal antibodies may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies). Thus, the hybridoma cells can serve as a useful source of DNA encoding antibodies with the desired properties. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as bacteria (e.g., E. coli), yeast (e.g., Saccharomyces or Pichia sp.), COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce antibody, to produce the monoclonal antibodies.
[0171] In some embodiments, monoclonal antibodies are produced by a cell-free system, such as the cell-free system disclosed herein or know in the art, e.g., as described in Yin et al., mAbs, 2012, 4:217-225; Hanson J et al., An Integrated In Vivo / In Vitro Protein Production Platform for Site-Specific Antibody Drug Conjugates, Bioengineering (Basel). 2023 Feb 28;10(3):304; using cell free extracts from a eukaryotic cell or a prokaryotic cell such as E coli.9.3. Humanized Antibodies341107438300\1\AMERICASAttorney Docket No. 108843.00624
[0172] Humanized antibodies may be generated by replacing most, or all, of the structural portions of a non-human monoclonal antibody with corresponding human antibody sequences. Consequently, a hybrid molecule is generated in which only the antigen-specific variable, or CDR, is composed of non-human sequence. Methods to obtain humanized antibodies include those described in, for example, Winter and Milstein, Nature, 1991, 349:293-299; Rader et al., Proc. Nat. Acad. Sci. U. S. A., 1998, 95:8910-8915; Steinberger et al., J. Biol. Chem., 2000, 275:36073-36078; Queen et al., Proc. Natl. Acad. Sci. U. S. A., 1989, 86:10029-10033; and U. S. Patent NOs 5,585,089, 5,693,761, 5,693,762, and 6,180,370; each of which is incorporated by reference in its entirety.
[0173] In some embodiments, an isolated antibody that binds to avP6 has been humanized.
[0174] In some embodiments, the humanized antibody comprises one or more framework regions of a VH comprising any one of SEQ ID NOS: 1244-1491. In some embodiments, the humanized antibody comprises one or more framework regions of a VL comprising the sequence set forth in SEQ ID NO: 1495.9.4. Human Antibodies
[0175] Human antibodies can be generated by a variety of techniques known in the art, for example by using transgenic animals (e.g., humanized mice). See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. U. S. A., 1993, 90:2551; Jakobovits et al., Nature, 1993, 362:255-258; Bruggermann et al., Year in Immuno., 1993, 7:33; and U. S. Patent NOs 5,591,669, 5,589,369 and 5,545,807; each of which is incorporated by reference in its entirety. Human antibodies can also be derived from phage-display libraries (see e.g., Hoogenboom et al., J. Mol. BioL, 1991, 227:381-388; Marks et al., J. Mol. Biol., 1991, 222:581-597; and U. S. Pat. NOs 5,565,332 and 5,573,905; each of which is incorporated by reference in its entirety). Human antibodies may also be generated by in vitro activated B cells (see e.g., U. S. Patent. NOs 5,567,610 and 5,229,275, each of which is incorporated by reference in its entirety). Human antibodies may also be derived from yeast-based libraries (see e.g., U. S. Patent No. 8,691,730, incorporated by reference in its entirety).10. ANTIBODY CONJUGATESAntibody Drug Conjugates (ADCs)
[0176] In some aspects, the present disclosure provides antibody conjugates comprising an isolated anti-avP6 antibody described herein linked to at least one payload optionally via a linker, wherein the payload is a cytotoxic agent.
[0177] In some embodiments, the payload is a cytotoxic payload. Non-limiting examples of a cytotoxic payload include a tubulin inhibitor, a DNA topoisomerase I inhibitor, and a DNA 351107438300\1\AMERICASAttorney Docket No. 108843.00624topoisomerase II inhibitor. In some embodiments, the payload is a DNA topoisomerase I inhibitor selected from the group consisting of irinotecan, SN-38, topotecan, and exatecan. In some embodiments, the payload is a DNA topoisomerase II inhibitor selected from the group consisting of etoposide, teniposide, and tafluposide. In some embodiments, the payload is selected from the group consisting of hemiasterlins, camptothecins, and anthracy clines. Anthracyclines may include PNU-159682 and EDA PNU-159682 derivatives. In some embodiments, the payload is an anthracycline selected from the group consisting of daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, and valrubicin. In some embodiments, the payload is hemiasterlin, exatecan, PNU-159682, or an EDA PNU-159682 derivative.
[0178] In some embodiments, the payload is an alkylating agent. In some embodiments, the payload is a bifunctional alkylator. In some embodiments, the payload is a bifunctional alkylator selected from the group consisting of cyclophosphamide, mechlorethamine, chlorambucil, and melphalan. In some embodiments, the payload is a monofunctional alkylator. In some embodiments, the payload is a monofunctional alkylator selected from the group consisting of dacabazine, nitrosourea, and temozolomide. In some embodiments, the payload is a cytoskeletal disruptor (e.g., a taxane). In some embodiments, the payload is a cytoskeletal disruptor selected from the group consisting of paclitaxel, docetaxel, abraxane, and taxotere. In some embodiments, the payload is an epothilone. In some embodiments, the payload is an epothilone selected from the group consisting of epothilone A, epothilone B, epothilone C, epothilone D, and ixabepilone. In some embodiments, the payload is a histone deacetylase inhibitor. In some embodiments, the payload is a histone deacetylase inhibitor selected from the group consisting of vorinostat and romidepsin. In some embodiments, the payload is a kinase inhibitor. In some embodiments, the payload is a kinase inhibitor selected from the group consisting of bortezomib, erlotinib, gefitinib, imatinib, vemurafenib, and vismodegib. In some embodiments, the payload is a nucleotide analog and / or precursor analog. In some embodiments, the payload is a nucleotide analog and / or precursor analog selected from the group consisting of azacitidine, azathioprine, capecitabine, cyatarabine, doxifluridine, fluorouracil, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, and tioguanine (formerly thioguanine). In some embodiments, the payload is a peptide antibiotic. In some embodiments, the payload is a peptide antibiotic selected from the group consisting of bleomycin and actinomycin. In some embodiments, the payload is a platinum-based agent. In some embodiments, the payload is a platinum-based agent selected from the group consisting of carboplatin, cisplatin, and oxaliplatin. In some embodiments, the payload is a retinoid. In some embodiments, the payload is a retinoid selected361107438300\1\AMERICASAttorney Docket No. 108843.00624from the group consisting of tretinoin, alitretinoin, and bexarotene. In some embodiments, the payload is a vinca alkaloid and derivatives thereof. In some embodiments, the payload is a vinca alkaloid and derivatives thereof selected from the group consisting of vinblastine, vincristine, vindesine, and vinorelbine.
[0179] In one embodiment, the payload is a residue of a cytotoxic agent selected from the group consisting of an alkylating agent, a DNA-crosslinking agent, an anti-tumor antibiotic, an anti-metabolite, an anti-mitotic agent, a histone-deacetylase (HDAC) inhibitor, a telomerase inhibitor, an immunogenic cell death agent, a tubulin inhibitor, and a topoisomerase inhibitor, or derivative thereof. In one embodiment, the cytotoxic agent is a topoisomerase inhibitor and the topoisomerase inhibitor is a topoisomerase I inhibitor or derivative thereof. In one embodiment, the topoisomerase I inhibitor is selected from the group consisting of camptothecin, irinotecan, SN-38, topotecan, and exatecan, or a derivative thereof. In one embodiment, the topoisomerase I inhibitor is exatecan or a derivative thereof. In one embodiment, the cytotoxic agent is a tubulin inhibitor. In one embodiment, the tubulin inhibitor is a hemiasterlin, a maytansine, or derivative thereof.
[0180] In addition to the payloads described above, the molecular payload can be any molecular entity that one of skill in the art might desire to conjugate to the polypeptide. In certain embodiments, the payload is a therapeutic moiety. In such embodiment, the antibody conjugate can be used to target the therapeutic moiety to its molecular target. In certain embodiments, the payload is a labeling moiety. In such embodiments, the antibody conjugate can be used to detect binding of the polypeptide to its target. In certain embodiments, the payload is a cytotoxic moiety. In such embodiments, the antibody conjugate can be used to target the cytotoxic moiety to a diseased cell, for example a cancer cell, to initiate destruction or elimination of the cell. Conjugates comprising other molecular payloads apparent to those of skill in the art are within the scope of the conjugates described herein.
[0181] In certain embodiments, an antibody conjugate can have a payload selected from the group consisting of a label, a dye, a polymer, a water-soluble polymer, polyethylene glycol, a derivative of polyethylene glycol, a photocrosslinker, a cytotoxic compound, a radionuclide, a drug, an affinity label, a photoaffinity label, a reactive compound, a resin, a second protein or polypeptide or polypeptide analog, an antibody or antibody fragment, a metal chelator, a cofactor, a fatty acid, a carbohydrate, a polynucleotide, a DNA, a RNA, an antisense polynucleotide, a peptide, a water-soluble dendrimer, a cyclodextrin, an inhibitory ribonucleic acid, a biomaterial, a nanoparticle, a spin label, a fluorophore, a metal -containing moiety, a radioactive moiety, a novel functional group, a group that covalently or noncovalently interacts371107438300\1\AMERICASAttorney Docket No. 108843.00624with other molecules, a photocaged moiety, a photoisomerizable moiety, biotin, a derivative of biotin, a biotin analogue, a moiety incorporating a heavy atom, a chemically cleavable group, a photocleavable group, an elongated side chain, a carbon-linked sugar, a redox-active agent, an amino thioacid, a toxic moiety, an isotopically labeled moiety, a biophysical probe, a phosphorescent group, a chemiluminescent group, an electron dense group, a magnetic group, an intercalating group, a chromophore, an energy transfer agent, a biologically active agent, a detectable label, a small molecule, or any combination thereof. In an embodiment, the payload is a label, a dye, a polymer, a cytotoxic compound, a radionuclide, a drug, an affinity label, a resin, a protein, a polypeptide, a polypeptide analog, an antibody, antibody fragment, a metal chelator, a cofactor, a fatty acid, a carbohydrate, a polynucleotide, a DNA, a RNA, a peptide, a fluorophore, or a carbon-linked sugar. In another embodiment, the payload is a label, a dye, a polymer, a drug, an antibody, antibody fragment, a DNA, an RNA, or a peptide.
[0182] Useful drug payloads include any cytotoxic or cytostatic agent. Useful classes of cytotoxic agents include, for example, antitubulin agents, auristatins, DNA minor groove binders, DNA replication inhibitors, alkylating agents (e.g., platinum complexes such as cisplatin, mono(platinum), bis(platinum) and tri-nuclear platinum complexes and carboplatin), anthracyclines, antibiotics, antifolates, antimetabolites, calmodulin inhibitors, chemotherapy sensitizers, duocarmycins, etoposides, fluorinated pyrimidines, ionophores, lexitropsins, maytansinoids, nitrosoureas, platinols, pore-forming compounds, purine antimetabolites, puromycins, radiation sensitizers, rapamycins, steroids, taxanes, topoisomerase inhibitors, vinca alkaloids, or the like.
[0183] Individual cytotoxic agents include, for example, an androgen, anthramycin (AMC), asparaginase, 5-azacytidine, azathioprine, bleomycin, busulfan, buthionine sulfoximine, calicheamicin, calicheamicin derivatives, camptothecin, carboplatin, carmustine (BSNU), CC-1065, chlorambucil, cisplatin, colchicine, cyclophosphamide, cytarabine, cytidine arabinoside, cytochalasin B, dacarbazine, dactinomycin (formerly actinomycin), daunorubicin, decarbazine, DM1, DM4, docetaxel, doxorubicin, etoposide, an estrogen, 5-fluordeoxyuridine, 5-fluorouracil, gemcitabine, gramicidin D, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine (CCNU), maytansine, mechlorethamine, melphalan, 6-mercaptopurine, methotrexate, mithramycin, mitomycin C, mitoxantrone, nitroimidazole, paclitaxel, palytoxin, plicamycin, procarbizine, rhizoxin, streptozotocin, tenoposide, 6-thioguanine, thioTEPA, topotecan, vinblastine, vincristine, vinorelbine, VP- 16 and VM-26.
[0184] In some embodiments, suitable cytotoxic agents include, for example, DNA minor groove binders (e.g., enediynes and lexitropsins, a CBI compound; see also U. S. Pat. No.381107438300\1\AMERICASAttorney Docket No. 108843.006246,130,237), duocarmycins, taxanes (e.g., paclitaxel and docetaxel), puromycins, vinca alkaloids, CC-1065, SN-38, topotecan, morpholino-doxorubicin, rhizoxin, cyanomorpholino-doxorubicin, echinomycin, combretastatin, netropsin, epothilone A and B, estramustine, cryptophycins, cemadotin, maytansinoids, discodermolide, eleutherobin, and mitoxantrone.
[0185] In some embodiments, the payload is an anti-tubulin agent. Examples of anti-tubulin agents include, but are not limited to, taxanes (e.g., Taxol® (paclitaxel), Taxotere® (docetaxel)), T67 (Tularik) and vinca alkyloids (e.g., vincristine, vinblastine, vindesine, and vinorelbine). Other anti-tubulin agents include, for example, baccatin derivatives, taxane analogs, epothilones (e.g., epothilone A and B), nocodazole, colchicine and colcimid, estramustine, cryptophycins, cemadotin, maytansinoids, combretastatins, discodermolide, and eleutherobin.
[0186] In certain embodiments, the cytotoxic agent is a maytansinoid, another group of anti-tubulin agents. For example, in specific embodiments, the maytansinoid can be maytansine or DM1 (ImmunoGen, Inc.; see also Chari etal., 1992, Cancer Res. 52:127-131).
[0187] In some embodiments, the payload is an auristatin, such as auristatin E or a derivative thereof. For example, the auristatin E derivative can be an ester formed between auristatin E and a keto acid. For example, auristatin E can be reacted with paraacetyl benzoic acid or benzoyl valeric acid to produce AEB and AEVB, respectively. Other typical auristatin derivatives include AFP (auristatin phenylalanine phenylenediamine), MMAF (monomethyl auristatin F), and MMAE (monomethyl auristatin E). The synthesis and structure of auristatin derivatives are described in U. S. Patent Application Publication Nos. 2003-0083263, 2005-0238649 and 2005-0009751; International Patent Publication No. WO 04 / 010957, International Patent Publication No. WO 02 / 088172, and U. S. Pat. Nos. 6,323,315; 6,239,104; 6,034,065; 5,780,588; 5,665,860; 5,663,149; 5,635,483; 5,599,902; 5,554,725; 5,530,097; 5,521,284; 5,504,191; 5,410,024; 5,138,036; 5,076,973; 4,986,988; 4,978,744; 4,879,278; 4,816,444; and 4,486,414.
[0188] In some embodiments, the payload is a hemiasterlin. Hemiasterlins suitable for use in the antibody-drug conjugates described herein are described, for example, in International Patent Publication No. WO 2016 / 2016 / 123582, which is incorporated herein by reference in its entirety.
[0189] In some embodiments, the payload is not a radioisotope. In some embodiments, the payload is not radioactive.
[0190] In some embodiments, the payload is an antimetabolite. The antimetabolite can be, for example, a purine antagonist (e.g., azothioprine or my cophenolate mofetil), a dihydrofolate reductase inhibitor (e.g., methotrexate), acyclovir, gangcyclovir, zidovudine, vidarabine,391107438300\1\AMERICASAttorney Docket No. 108843.00624ribavarin, azidothymidine, cytidine arabinoside, amantadine, dideoxyuridine, iododeoxyuridine, poscamet, or trifluridine.
[0191] In other embodiments, the payload is tacrolimus, cyclosporine, FU506 or rapamycin. In further embodiments, the Drug is aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, amifostine, anastrozole, arsenic trioxide, bexarotene, bexarotene, calusterone, capecitabine, celecoxib, cladribine, Darbepoetin alfa, Denileukin diftitox, dexrazoxane, dromostanolone propionate, epirubicin, Epoetin alfa, estramustine, exemestane, Filgrastim, floxuridine, fludarabine, fulvestrant, gemcitabine, gemtuzumab ozogamicin (MYLOTARG), goserelin, idarubicin, ifosfamide, imatinib mesylate, Interferon alfa-2a, irinotecan, letrozole, leucovorin, levamisole, meclorethamine or nitrogen mustard, megestrol, mesna, methotrexate, methoxsalen, mitomycin C, mitotane, nandrolone phenpropionate, oprelvekin, oxaliplatin, pamidronate, pegademase, pegaspargase, pegfilgrastim, pentostatin, pipobroman, a pladienolide, plicamycin, porfimer sodium, procarbazine, quinacrine, rasburicase, Rituximab, Sargramostim, streptozocin, tamoxifen, temozolomide, teniposide, testolactone, thioguanine, toremifene, Tositumomab, Trastuzumab (HERCEPTIN), tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine or zoledronate.
[0192] Other useful drug payloads include chemical compounds useful in the treatment of cancer. Examples of chemotherapeutic agents include Erlotinib (TARCEVA®, Genentech / OSI Pharm.), Bortezomib (VELCADE®, Millennium Pharm.), Fulvestrant (FASLODEX®, AstraZeneca), Sutent (SU11248, Pfizer), Letrozole (FEMARA®, Novartis), Imatinib mesylate (GLEEVEC®, Novartis), PTK787 / ZK 222584 (Novartis), Oxaliplatin (Eloxatin®, Sanofi), 5-FU (5 -fluorouracil), Leucovorin, Rapamycin (Sirolimus, RAPAMUNE®, Wyeth), Lapatinib (TYKERB®, GSK572016, Glaxo Smith Kline), Lonafamib (SCH 66336), Sorafenib (BAY43-9006, Bayer Labs), and Gefitinib (IRESSA®, AstraZeneca), AG1478, AG1571 (SU 5271; Sugen), alkylating agents such as thiotepa and CYTOXAN® cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analog topotecan); bryostatin; cally statin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogs); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogs, KW-2189 and CB1-TM1); eleutherobin; pancrati statin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlomaphazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine,401107438300\1\AMERICASAttorney Docket No. 108843.00624mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as the enediyne antibiotics (e.g., calicheamicin, especially uncialamycin, calicheamicin gammall, and calicheamicin omegall (Angew Chem. Inti. Ed. Engl. (1994) 33:183-186); dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN® (doxorubicin), morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5 -fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pladienolide B, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamniprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin; sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2, 2', 2"-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside (“Ara-C”); cyclophosphamide; thiotepa; taxoids, e.g., TAXOL® (paclitaxel; Bristol-Myers Squibb Oncology, Princeton, N. J.), ABRAXANE® (Cremophor-free), albumin-engineered nanoparticle formulations of paclitaxel (American Pharmaceutical Partners, Schaumberg, Ill.), and TAXOTERE® (doxetaxel; Rhone-Poulenc Rorer, Antony, France); chloranmbucil; GEMZAR® (gemcitabine); 6-thioguanine;411107438300\1\AMERICASAttorney Docket No. 108843.00624mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; etoposide (VP- 16); ifosfamide; mitoxantrone; vincristine; NAVELBINE® (vinorelbine); novantrone; teniposide; edatrexate; daunomycin; aminopterin; capecitabine (XELODA®); ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; and pharmaceutically acceptable salts, acids and derivatives of any of the above.
[0193] Other useful payloads include: (i) anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti -estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEX®; tamoxifen citrate), raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and FARESTON® (toremifine citrate); (ii) aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, MEGASE® (megestrol acetate), AROMASIN® (exemestane; Pfizer), formestanie, fadrozole, RIVISOR® (vorozole), FEMARA® (letrozole; Novartis), and ARIMIDEX® (anastrozole; AstraZeneca); (iii) anti -androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; as well as troxacitabine (a 1,3 -di oxolane nucleoside cytosine analog); (iv) protein kinase inhibitors; (v) lipid kinase inhibitors; (vi) antisense oligonucleotides, particularly those which inhibit expression of genes in signaling pathways implicated in aberrant cell proliferation, such as, for example, PKC-alpha, Ralf and H-Ras; (vii) ribozymes such as VEGF expression inhibitors (e.g., ANGIOZYME®) and HER2 expression inhibitors; (viii) vaccines such as gene therapy vaccines, for example, ALLOVECTIN®, LEUVECTIN®, and VAXID®; PROLEUKIN® rIL-2; a topoisomerase 1 inhibitor such as LURTOTECAN®; ABARELIX® rmRH; (ix) anti-angiogenic agents such as bevacizumab (AVASTIN®, Genentech); (x) agents that act to regulate or inhibit activity of members of the poly(ADP -ribose) polymerase (PARP) family in tumors (e.g., Talazoparib (BMN-673), Iniparib (BSI 201), Veliparib (ABT-888), Olaparib (AZD-2281, trade name LYNPARZA™), Rucaparib (AG 014699), BGB-290, E7016, E7449, and CEP-9722); (xi) agents that act to regulate or inhibit activity of members of the histone deacetylase (HD AC) family in tumors (e.g., abexinostat, entinostat, gavinostat, 4SC-202, ACY-241, AR-42, CG200745, CHR-2845, CHR-3996, CXD101, MPT0E028, OBP-801, SHP-141, CUDC-101, KA2507, panobinostat, pracinostat, quisinostat, resminostat, ricolinostat); (xii) agents that act to regulate or inhibit activity of mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2) in tumors (e.g., enasidenib mesylate (CC-90007, AG-221 mesylate); and (xiii) pharmaceutically acceptable salts, acids and derivatives of any of the above. Other useful payloads include anti-angiogenic agents, including,421107438300\1\AMERICASAttorney Docket No. 108843.00624e.g., MMP-2 (matrix-metalloproteinase 2) inhibitors, MMP-9 (matrix-metalloproteinase 9) inhibitors, COX-II (cyclooxygenase II) inhibitors, and VEGF receptor tyrosine kinase inhibitors. Examples of such useful matrix metalloproteinase inhibitors that can be used in combination with the present compounds / compositions are described in WO 96 / 33172, WO 96 / 27583, EP 818442, EP 1004578, WO 98 / 07697, WO 98 / 03516, WO 98 / 34918, WO 98 / 34915, WO 98 / 33768, WO 98 / 30566, EP 606,046, EP 931,788, WO 90 / 05719, WO 99 / 52910, WO 99 / 52889, WO 99 / 29667, WO 99 / 07675, EP 945864, U. S. Pat. No. 5,863,949, U. S. Pat. No.5,861,510, and EP 780,386, all of which are incorporated herein in their entireties by reference. Examples of VEGF receptor tyrosine kinase inhibitors include 4-(4-bromo-2-fluoroanilino)-6- methoxy-7-(l-methylpiperidin-4-ylmethoxy)quinazoline (ZD6474; Example 2 within WO 01 / 32651), 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-l- ylpropoxy)quinazoline (AZD2171; Example 240 within WO 00 / 47212), vatalanib (PTK787; WO 98 / 35985) and SU11248 (sunitinib; WO 01 / 60814), and compounds such as those disclosed in PCT Publication Nos. WO 97 / 22596, WO 97 / 30035, WO 97 / 32856, and WO 98 / 13354).
[0001] In some aspects, the present disclosure provides antibody conjugates comprising an isolated anti-avP6 antibody described herein linked to at least one payload optionally via a linker, wherein the payload is an immunomodulatory agent. An immunomodulatory agent is an agent capable of regulating (e.g., stimulating or suppressing) the immune system of a subject. In some embodiments, the immunomodulatory agent is independently an agonist of stimulator of interferon gene (STING), Toll-like receptor 7 (TLR7), Toll-like receptor 7 / 8 (TLR7 / 8), or Tolllike receptor 8 (TLR8). In some embodiments, the immunomodulatory agent is independently an agonist of STING. In some embodiments, the immunomodulatory agent is independently an agonist of Toll-like receptor 7 (TLR7). In some embodiments, the immunomodulatory agent is independently an agonist of Toll-like receptor 7 / 8 (TLR7 / 8). In some embodiments, the immunomodulatory agent is independently an agonist of Toll-like receptor 8 (TLR8). In some embodiments, the agonist of STING is independently selected from the group consisting of a small molecule agonist of the STING pathway, an antibody that activates STING activity, a recombinant protein that activates the STING pathway, TTI-10001, DMXAA (ASA404), CDNs, c-di-GMP, 2'3'-cGAMP, MK-1454, ADU-S100 (MIW815), SB11285, ADU-V19, IACS-8779, IACS-8803, IMSA101, non-CDNs, E7766, MK-2118, diABZI, MSA-2, JNJ-‘6196, bacterial vectors, SYNB1891, and STACT (see, e.g., Luo etal. Molecules 2022, 27, 4638, the contents of which are incorporated herein by reference in their entirety). In some embodiments, the agonist of STING is independently a small molecule agonist of the STING pathway. In some embodiments, the agonist of STING is independently an antibody that activates STING activity.431107438300\1\AMERICASAttorney Docket No. 108843.00624In some embodiments, the agonist of STING is independently a recombinant protein that activates the STING pathway. In some embodiments, the agonist of STING is TTI-10001. In some embodiments, the agonist of STING is DMXAA (ASA404). In some embodiments, the agonist of STING is a CDN(s). In some embodiments, the agonist of STING is c-di-GMP. In some embodiments, the agonist of STING is 2'3'-cGAMP. In some embodiments, the agonist of STING is MK-1454. In some embodiments, the agonist of STING is ADU-S100 (MIW815). In some embodiments, the agonist of STING is SB 11285. In some embodiments, the agonist of STING is ADU-V19. In some embodiments, the agonist of STING is IACS-8779. In some embodiments, the agonist of STING is IACS-8803. In some embodiments, the agonist of STING is IMSA101. In some embodiments, the agonist of STING is a non-CDN(s). In some embodiments, the agonist of STING is E7766. In some embodiments, the agonist of STING is MK-2118. In some embodiments, the agonist of STING is diABZI. In some embodiments, the agonist of STING is MSA-2. In some embodiments, the agonist of STING is JNJ-‘6196. In some embodiments, the agonist of STING is a bacterial vector(s). In some embodiments, the agonist of STING is SYNB1891. In some embodiments, the agonist of STING is STACT. In some embodiments, the agonist of STING is a bacterial vector(s). Additional examples of STING agonists also include those described in WO 2025 / 029832, which is incorporated by reference herein in its entirety. In some embodiments, the agonist of Toll-like receptor 7 (TLR7) is independently selected from the group consisting of GS-986, PRTX-007, PRX-034, S-34240, MBS-8, and APR-002 (see, e.g., Bhagchandani et al. Advanced Drug Delivery Reviews 2021, 775, 113803, the contents of which are incorporated by reference in their entirety). In some embodiments, the agonist of Toll-like receptor 7 (TLR7) is GS-986. In some embodiments, the agonist of Toll -like receptor 7 (TLR7) is PRTX-007. In some embodiments, the agonist of Tolllike receptor 7 (TLR7) is PRX-034. In some embodiments, the agonist of Toll-like receptor 7 (TLR7) is S-34240. In some embodiments, the agonist of Toll-like receptor 7 (TLR7) is MBS- 8. In some embodiments, the agonist of Toll-like receptor 7 (TLR7) is APR-002.
[0002] In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is independently selected from the group consisting of imiquimod (R837), resiquimod (R848), 852-A (PF- 4878691), vesatolimod (GS-9620), AZD8848, motolimod (VTX-2337), selgantolimod (GS- 9688), NKTR-262, RG-7854 (RO 7020531), DSP-0509, BDB-001, BDC-1001, LHC-165, SHR- 2150, JNJ-4964 (TQ-73334), RO-7119929, DN-1508052, VTX-1463, BNT-411 (SCI), APR- 003, ALT-702, TRANSCON, VX-001, SNAPvax, R848-HA, SM360320, and GSK2245035 (see, e.g., Bhagchandani et al. Advanced Drug Delivery Reviews 2021, 775, 113803; and Evans etal. ACS Omega 2019, 4, 13, 15665, the contents of each are incorporated by reference in their441107438300\1\AMERICASAttorney Docket No. 108843.00624entirety). In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is imiquimod (R837). In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is resiquimod (R848). In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is 852-A (PF- 4878691). In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is vesatolimod (GS-9620). In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is AZD8848. In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is motolimod (VTX-2337). In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is selgantolimod (GS- 9688). In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is NKTR-262. In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is RG-7854 (RO 7020531). In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is DSP-0509. In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is BDB-001. In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is BDC-1001. In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is LHC-165. In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is SHR-2150. In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is JNJ-4964 (TQ-73334). In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is RO-7119929. In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is DN-1508052. In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is VTX- 1463. In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is BNT-411 (SCI). In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is APR-003. In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is ALT-702. In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is TRANSCON. In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is VX-001. In some embodiments, the agonist of Tolllike receptor 7 / 8 (TLR7 / 8) is SNAPvax. In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is R848-HA. In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is SM360320. In some embodiments, the agonist of Toll-like receptor 7 / 8 (TLR7 / 8) is GSK2245035.
[0003] In some embodiments, the agonist of Toll-like receptor 8 (TLR8) is independently selected from the group consisting of SBT-6050, SBT-6290, and ZM-TLR8 agonist. In some embodiments, the agonist of Toll-like receptor 8 (TLR8) is SBT-6050. In some embodiments, the agonist of Toll-like receptor 8 (TLR8) is SBT-6290. In some embodiments, the agonist of Toll-like receptor 8 (TLR8) is ZM-TLR8 agonist.
[0194] Additional examples of STING agonists and TLR agonists also include those described in W02020252015, which is incorporated by reference herein in its entirety.451107438300\1\AMERICASAttorney Docket No. 108843.00624
[0195] In any of the foregoing embodiments, the bracketed structure can be covalently bonded to one or more non-natural amino acids of the antibody, wherein the one or more nonnatural amino acids are located at sites selected from the group consisting of: HC-F404, HC-Y391, HC-Y180, HC-F241, LC-42 (e.g., LC-K42 or LC-Q42 depending on the framework), and LC-E161, according to the Kabat or EU numbering scheme of Kabat. In some embodiments, the bracketed structure is covalently bonded to one or more non-natural amino acids at site HC-F404 of the antibody. In some embodiments, the bracketed structure is covalently bonded to one or more non-natural amino acids at site HC-Y180 of the antibody. In some embodiments, the bracketed structure is covalently bonded to one or more non-natural amino acids at site HC-F241 of the antibody. In some embodiments, the bracketed structure is covalently bonded to one or more non-natural amino acids at site LC-42 (e.g., LC-K42 or LC-Q42) of the antibody. In some embodiments, the bracketed structure is covalently bonded to one or more non-natural amino acids at site LC-E161 of the antibody. In some embodiments, the bracketed structures are covalently bonded to non-natural amino acids at sites HC-F404 and HC-Y180 of the antibody. In some embodiments, the bracketed structures are covalently bonded to non-natural amino acids at sites HC-F404, HC-Y391, HC-Y180, and LC-42 (e.g., LC-K42 or LC-Q42) of the antibody. In some embodiments, the bracketed structures are covalently bonded to non-natural amino acids at sites HC-F404, HC-Y391, HC-Y180, LC-42 (e.g., LC-K42 or LC-Q42), and LC-E161 of the antibody. In some embodiments, the bracketed structures are covalently bonded to non-natural amino acids at sites HC-F404, HC-Y180, and HC-F241 of the antibody. In some embodiments, the bracketed structures are covalently bonded to non-natural amino acids at sites HC-F404, HC-Y391, HC-Y180, HC-F241, and LC-42 (e.g., LC-K42 or LC-Q42) of the antibody. In some embodiments, the antibody comprises one or more non-natural amino acids at HC-F404, HC-K121, HC-Y180, HC-F241, HC-221, HC-Y391, LC-T22, LC-S7, LC-N152, LC-K42, LC-E161, LC-D170, HC-S136, HC-S25, HC-A40, HC-S119, HC-S190, HC-K222, HC-R19, HC-Y52, HC-S70, or a combination thereof. In some embodiments, the antibody comprises one or more non-natural amino acids atHC-Y180, HC-F241, HC-Y391, HC-F404, or a combination thereof. In one example, the antibody comprises one or more non-natural amino acids HC-Y180, HC-F241, HC-Y391, and HC-F404.
[0196] In certain embodiments, the one or more non-natural amino acids is selected from the group consisting of p-acetyl-L-phenylalanine, O-methyl-L-tyrosine, an -3-(2-naphthyl)alanine, 3-methyl-phenylalanine, O-4-allyl-L-tyrosine, 4-propyl-L-tyrosine, a tri-O-acetyl-GlcNAcP-serine, L-Dopa, fluorinated phenylalanine, isopropyl-L-phenylalanine, p-azido-L-phenylalanine, p-azido-methyl-L-phenylalanine, p-acyl-L- phenylalanine, p-benzoyl-L-461107438300\1\AMERICASAttorney Docket No. 108843.00624phenylalanine, L-phosphoserine, phosphonoserine, phosphonotyrosine, p-iodo-phenylalanine, p-bromophenylalanine, p-amino-L-phenylalanine, isopropyl-L-phenylalanine, and p-propargyloxy-phenylalanine. In certain embodiments, the non-natural amino acid residue is a residue of p-azido-methyl-L-phenylalanine or p-acetyl-L-phenylalanine. Further examples of non-natural amino acids include those described in W02019055909, which is incorporated by reference herein in its entirety.
[0197] Useful linkers include those described herein. In certain embodiments, a linker is independently any divalent or multivalent linker known to those of skill in the art. Useful divalent linkers include alkylene, substituted alkylene, heteroalkylene, substituted heteroalkylene, arylene, substituted arylene, heteroarlyene, and substituted heteroarylene. In certain embodiments, a linker is Cnio alkylene or Cnio heteroalkylene. In some embodiments, the Ci-ioheteoalkylene is PEG.
[0198] In certain embodiments, the linker is hydrolytically stable. Hydrolytically stable linkages means that the linkages are substantially stable in water and do not react with water at useful pH values, including but not limited to, under physiological conditions for an extended period of time, perhaps even indefinitely. In certain embodiments, a linker is hydrolytically unstable. Hydrolytically unstable or degradable linkages mean that the linkages are degradable in water or in aqueous solutions, including for example, blood. Enzymatically unstable or degradable linkages mean that the linkage can be degraded by one or more enzymes.
[0199] In some embodiments, the linker is protease cleavable linker, an enzyme cleavable linker, a pH-sensitive linker, or a non-cleavable linker.
[0200] As understood in the art, PEG and related polymers may include degradable linkages in the polymer backbone or in the linker group between the polymer backbone and one or more of the terminal functional groups of the polymer molecule. For example, ester linkages formed by the reaction of PEG carboxylic acids or activated PEG carboxylic acids with alcohol groups on a biologically active agent generally hydrolyze under physiological conditions to release the agent.
[0201] Other hydrolytically degradable linkers include, but are not limited to, carbonate linkages; imine linkages resulted from reaction of an amine and an aldehyde; phosphate ester linkages formed by reacting an alcohol with a phosphate group; hydrazone linkages which are reaction product of a hydrazide and an aldehyde; acetal linkages that are the reaction product of an aldehyde and an alcohol; orthoester linkages that are the reaction product of a formate and an alcohol; peptide linkages formed by an amine group, including but not limited to, at an end of a polymer such as PEG, and a carboxyl group of a peptide; and oligonucleotide linkages formed471107438300\1\AMERICASAttorney Docket No. 108843.00624by a phosphoramidite group, including but not limited to, at the end of a polymer, and a 5' hydroxyl group of an oligonucleotide.
[0202] A number of different cleavable linkers are known to those of skill in the art. See U. S. Pat. Nos. 4,618,492; 4,542,225, and 4,625,014. The mechanisms for release of an agent from these linker groups include, for example, irradiation of a photolabile bond and acid-catalyzed hydrolysis. U. S. Pat. No. 4,671,958, for example, includes a description of immunoconjugates comprising linkers which are cleaved at the target site in vivo by the proteolytic enzymes of the patient's complement system. The length of the linker may be predetermined or selected depending upon a desired spatial relationship between the polypeptide and the molecule linked to it. In view of the large number of methods that have been reported for attaching a variety of radiodiagnostic compounds, radiotherapeutic compounds, drugs, toxins, and other agents to polypeptides one skilled in the art will be able to determine a suitable method for attaching a given agent to a polypeptide.
[0203] The linkers described herein may have a wide range of molecular weight or molecular length. Larger or smaller molecular weight linkers may be used to provide a desired spatial relationship or conformation between the polypeptide and the linked entity. Linkers having longer or shorter molecular length may also be used to provide a desired space or flexibility between the polypeptide and the linked entity. Similarly, a linker having a particular shape or conformation may be utilized to impart a particular shape or conformation to the polypeptide or the linked entity, either before or after the polypeptide reaches its target. The functional groups present on each end of the linker may be selected to modulate the release of a polypeptide or a payload under desired conditions. This optimization of the spatial relationship between the polypeptide and the linked entity may provide new, modulated, or desired properties to the molecule.
[0204] In some embodiments, provided herein are water-soluble bifunctional linkers that have a dumbbell structure that includes: a) an azide, an alkyne, a hydrazine, a hydrazide, a hydroxylamine, or a carbonyl-containing moiety on at least a first end of a polymer backbone; and b) at least a second functional group on a second end of the polymer backbone. The second functional group can be the same or different as the first functional group. The second functional group, in some embodiments, is not reactive with the first functional group. In some embodiments, water-soluble compounds that comprise at least one arm of a branched molecular structure are provided. For example, the branched molecular structure can be a dendritic structure.481107438300\1\AMERICASAttorney Docket No. 108843.00624
[0205] In some embodiments, a linker is derived from a linker precursor selected from the group consisting of: N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), N-succinimidyl 4-(2-pyridyldithio)pentanoate (SPP), N-succinimidyl 4-(2-pyridyldithio)butanoate (SPDB), N-succinimidyl-4-(2-pyridyldithio)-2-sulfo-butanoate (sulfo-SPDB), N-succinimidyl iodoacetate (SIA), N-succinimidyl(4-iodoacetyl)aminobenzoate (SIAB), maleimide PEG NHS, N-succinimidyl 4-(maleimidomethyl)cyclohexanecarboxylate (SMCC), N-sulfosuccinimidyl 4-(maleimidomethyl)cyclohexanecarboxylate (sulfo-SMCC) or 2,5-dioxopyrrolidin-l-yl 17-(2,5-di oxo-2, 5-dihydro- IH-pyrrol-l -yl)-5,8, 11, 14-tetraoxo-4,7, 10, 13 -tetraazaheptadecan- 1 -oate (CX1-1). In a specific embodiment, the linker is derived from the linker precursor N-succinimidyl 4-(maleimidomethyl)cyclohexanecarboxylate (SMCC).
[0206] In some embodiments, a linker is derived from a linker precursor selected from the group consisting of dipeptides, tripeptides, tetrapeptides, and pentapeptides. In such embodiments, the linker can be cleaved by a protease. Exemplary dipeptides include, but are not limited to, valine-citrulline (vc or val-cit), alanine-phenylalanine (af or ala-phe); phenylalaninelysine (fk or phe-lys); phenylalanine-homolysine (phe-homolys); and N-methyl-valine-citrulline (Me-val-cit). Exemplary tripeptides include, but are not limited to, glycine-valine-citrulline (gly-val-cit), glycine-glycine-glycine (gly-gly-gly), and glycine- methoxyethoxyethyl)serine-valine (gly-val-citalanine OMESerValAla).
[0207] In some embodiments, a linker described herein comprises a self-immolative spacer. In certain embodiments, the self-immolative spacer comprises p-aminobenzyl. In some embodiments, a p-aminobenzyl alcohol is attached to an amino acid unit via an amide bond, and a carbamate, methylcarbamate, or carbonate is made between the benzyl alcohol and the payload (Hamann etal. (2005) Expert Opin. Ther. Patents (2005) 15:1087-1103). In some embodiments, the linker comprises p-aminobenzyloxycarbonyl (PAB). Other examples of self-immolative spacers include, but are not limited to, aromatic compounds that are electronically similar to the PAB group, such as 2-aminoimidazol-5-methanol derivatives (U. S. Pat. No. 7,375,078; Hay et al. (1999) Bioorg. Med. Chem. Lett. 9:2237) and ortho- or para-aminobenzylacetals. In some embodiments, spacers can be used that undergo cyclization upon amide bond hydrolysis, such as substituted and unsubstituted 4-aminobutyric acid amides (Rodrigues et al. (1995) Chemistry Biology 2:223), appropriately substituted bicyclo[2.2.1] and bicyclo[2.2.2] ring systems (Storm et al. (1972) J. Amer. Chem. Soc. 94:5815) and 2-aminophenylpropionic acid amides (Amsberry, et al. (1990) J. Org. Chem. 55:5867). Linkage of a drug to the a-carbon of a glycine residue is another example of a self-immolative spacer that may be useful in conjugates (Kingsbury et al. (1984) J. Med. Chem. 27:1447).491107438300\1\AMERICASAttorney Docket No. 108843.00624
[0208] In certain embodiments, linker precursors can be combined to form larger linkers. For instance, in certain embodiments, linkers comprise the dipeptide valine-citrulline and p-aminobenzyloxycarbonyl. These are also referenced as citValCit— PAB linkers.
[0209] In some embodiments, one or more linkers in an antibody conjugate is hydrolytically stable. Alternatively or additionally, one or more linkers in an antibody conjugate is cleavable. Alternatively or additionally, one or more linkers in an antibody conjugate, is a protease cleavable linker, an enzyme cleavable linker, a pH-sensitive linker, or a non-cleavable linker.Preparation of Antibody Conjugates
[0210] The antibody conjugates can be prepared by standard techniques. In certain embodiments, an antibody is contacted with a payload precursor under conditions suitable for forming a bond from the antibody to the payload to form an antibody -pay load conjugate. In certain embodiments, an antibody is contacted with a linker precursor under conditions suitable for forming a bond from the antibody to the linker. The resulting antibody-linker is contacted with a payload precursor under conditions suitable for forming a bond from the antibody-linker to the payload to form an antibody-linker-payload conjugate. In certain embodiments, a payload precursor is contacted with a linker precursor under conditions suitable for forming a bond from the payload to the linker. The resulting payload-linker is contacted with an antibody under conditions suitable for forming a bond from the payload-linker to the antibody to form an antibody-linker-payload conjugate. Suitable linkers for preparing the antibody conjugates are disclosed herein, and exemplary conditions for conjugation are described in the Examples below.
[0211] The structures and synthesis of the payloads in the antibody conjugates herein, including those mentioned in the Example section below, include those described in WO2020257235, W02020252043, WO2016123582, and WO2022103983, each of which is incorporated by reference herein in its entirety.
[0212] In some embodiments, the antibody conjugates is produced by a cell-free system, such as the cell-free system disclosed herein or known in the art, e.g., as described in Yin et al., mAbs, 2012, 4:217-225; Hanson J et al., An Integrated In Vivo / In Vitro Protein Production Platform for Site-Specific Antibody Drug Conjugates, Bioengineering (Basel). 2023 Feb 28;10(3):304; using cell free extracts from a eukaryotic cell or a prokaryotic cell such as E coli.11. MULTI-SPECIFIC ANTIBODIES AND OTHER AVB6 BINDING MOLECULES
[0213] In some aspects, the present disclosure provides multi-specific antibodies (e.g., bispecific antibodies). The multispecific antibodies have binding specificities for at least two different epitopes. In some embodiments, the multi-specific antibodies bind to two different epitopes of a avP6 protein. In some embodiments, the multi-specific antibodies comprise an 501107438300\1\AMERICASAttorney Docket No. 108843.00624avP6-binding domain, and one or more binding domains for different protein(s). In some embodiments, the multi-specific antibodies may be used to localize cytotoxic agents to cells which express avP6. These antibodies may possess an avP6 binding domain and another domain that binds the cytotoxic agent. The multi-specific antibodies may be full length antibodies or antibody fragments (e.g., scFv, F(ab')2 and other antibody fragments disclosed herein). In some embodiments, a multi-specific antibody comprises two or more antigen binding domains, at least one of which comprises the CDRs and / or VH / VL sequences in the anti-avP6 antibodies disclosed herein.
[0214] In some aspects, the present disclosure provides chimeric antigen receptors (CARs) comprising a avP6-binding domain. In some embodiments, the avP6-binding domain may comprise the CDRs and / or VH / VL sequences in the anti-avP6 antibodies disclosed herein. In general, a chimeric antigen receptor (CAR) comprises at least two domains, which when expressed in a cell, provides the cell with specificity for a target antigen, or a target cell bearing a target antigen, typically a diseased cell bearing a specific disease-related antigen. In some embodiments, a CAR comprises at least an extracellular antigen binding domain (including a avP6 binding domain), a transmembrane domain and a cytoplasmic signaling domain (also referred to herein as “an intracellular signaling domain”) comprising a functional signaling domain derived from one or more stimulatory and / or costimulatory molecules as provided below. In some examples, the intracellular signaling domain of a CAR is derived from the CD3 zeta chain that is normally found associated with the TCR complex. The CD3 zeta signaling domain may be fused with one or more functional signaling domains derived from at least one co-stimulatory molecule such as 4-1BB, CD27 and / or CD28.12. VECTORS, HOST CELLS, AND RECOMBINANT METHODS
[0215] The invention also provides isolated nucleic acids encoding anti-avP6 antibodies, vectors and host cells comprising the nucleic acids, and recombinant techniques for the production of the antibodies.
[0216] For recombinant production of the antibody, the nucleic acid(s) encoding it may be isolated and inserted into a replicable vector for further cloning (i.e., amplification of the DNA) or expression. In some aspects, the nucleic acid may be produced by homologous recombination, for example as described in U. S. Patent No. 5,204,244, incorporated by reference in its entirety.
[0217] Many different vectors are known in the art. The vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription511107438300\1\AMERICASAttorney Docket No. 108843.00624termination sequence, for example as described in U. S. Patent No. 5,534,615, incorporated by reference in its entirety.
[0218] Illustrative examples of suitable host cells are provided below. These host cells are not meant to be limiting.
[0219] Suitable host cells include any prokaryotic (e.g., bacterial), lower eukaryotic (e.g., yeast), or higher eukaryotic (e.g., mammalian) cells. Suitable prokaryotes include eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterob acteriaceae such as Escherichia (E. coli), Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella (S. typhimurium), Serratia (S. marcescans), Shigella, Bacilli (B. subtilis and B. licheniformis), Pseudomonas (P. aeruginosa), and Streptomyces. One useful E. coli cloning host is E. coli 294, although other strains such as E. coli B, E. coli XI 776, and E. coli W3110 are suitable.
[0220] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are also suitable cloning or expression hosts for anti-avP6 antibody-encoding vectors. Saccharomyces cerevisiae, or common baker’s yeast, is a commonly used lower eukaryotic host microorganism. However, a number of other genera, species, and strains are available and useful, such as Schizosaccharomyces pombe, Kluyveromyces (K. lactis, K. fragilis, K. bulgaricus K. wickeramii, K. waltii, K. drosophilarum, K. thermotolerans, and K. marxianus), Yarrowia, Pichia pastoris, Candida (C. albicans), Trichoderma reesia, Neurospora crassa, Schwanniomyces (S. occidentalis), and filamentous fungi such as, for example Penicillium, Tolypocladium, and Aspergillus (A. nidulans and A. niger).
[0221] Useful mammalian host cells include COS-7 cells, HEK293 cells; baby hamster kidney (BHK) cells; Chinese hamster ovary (CHO); mouse sertoli cells; African green monkey kidney cells (VERO-76), and the like.
[0222] The host cells used to produce the anti-avP6 antibody of this invention may be cultured in a variety of media. Commercially available media such as, for example, Ham’s F10, Minimal Essential Medium (MEM), RPMI-1640, and Dulbecco’s Modified Eagle’s Medium (DMEM) are suitable for culturing the host cells. In addition, any of the media described in Ham et al., Meth. Enz., 1979, 58:44; Barnes et al., Anal. Biochem., 1980, 102:255; and U. S. Patent NOs 4,767,704, 4,657,866, 4,927,762, 4,560,655, and 5,122,469, or WO 90 / 03430 and WO 87 / 00195 may be used. Each of the foregoing references is incorporated by reference in its entirety.
[0223] Any of these media may be supplemented as necessary with hormones and / or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as521107438300\1\AMERICASAttorney Docket No. 108843.00624adenosine and thymidine), antibiotics, trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art.
[0224] The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
[0225] When using recombinant techniques, the antibody can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If the antibody is produced intracellularly, as a first step, the particulate debris, either host cells or lysed fragments, is removed, for example, by centrifugation or ultrafiltration. For example, Carter et al. (Bio Technology. 1992, 10:163-167) describes a procedure for isolating antibodies which are secreted to the periplasmic space of E. coli. Briefly, cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonylfluoride (PMSF) over about 30 min. Cell debris can be removed by centrifugation.
[0226] In some embodiments, the antibody is produced in a cell-free system. In some aspects, the cell-free system is an in vitro transcription and translation system as described in Yin et al., mAbs, 2012, 4:217-225, incorporated by reference in its entirety. In some aspects, the cell-free system utilizes a cell-free extract from a eukaryotic cell or from a prokaryotic cell. In some aspects, the prokaryotic cell is E. coli. Cell-free expression of the antibody may be useful, for example, where the antibody accumulates in a cell as an insoluble aggregate, or where yields from periplasmic expression are low. In some aspects, the cell-free system is a XpressCF+® cell-free protein synthesis system, e.g., as described in Hanson J et al., An Integrated In Vivo / In Vitro Protein Production Platform for Site-Specific Antibody Drug Conjugates, Bioengineering (Basel). 2023 Feb 28;10(3):304, which is incorporated by reference herein in its entirety.
[0227] Where the antibody is secreted into the medium, supernatants from such expression systems are generally first concentrated using a commercially available protein concentration filter, for example, an Amicon® or Millipore® Pellcon® ultrafiltration unit. A protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis and antibiotics may be included to prevent the growth of adventitious contaminants.
[0228] The antibody composition prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being a particularly useful purification technique. The suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc531107438300\1\AMERICASAttorney Docket No. 108843.00624domain that is present in the antibody. Protein A can be used to purify antibodies that are based on human yl, y2, or y4 heavy chains (Lindmark et al., J. Immunol. Meth., 1983, 62:1-13, incorporated by reference in its entirety). Protein G is useful for all mouse isotypes and for human y3 (Guss et al., EMBO J., 1986, 5:1567-1575, incorporated by reference in its entirety).
[0229] The matrix to which the affinity ligand is attached is most often agarose, but other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be achieved with agarose. Where the antibody comprises a CH3 domain, the BakerBond ABX® resin is useful for purification.
[0230] Other techniques for protein purification, such as fractionation on an ion-exchange column, ethanol precipitation, Reverse Phase HPLC, chromatography on silica, chromatography on heparin Sepharose®, chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation are also available, and can be applied by one of skill in the art.
[0231] Following any preliminary purification step(s), the mixture comprising the antibody of interest and contaminants may be subjected to low pH hydrophobic interaction chromatography using an elution buffer at a pH between about 2.5 to about 4.5, generally performed at low salt concentrations (e.g., from about 0 to about 0.25 M salt).13. PHARMACEUTICAL COMPOSITIONS AND METHODS OF ADMINISTRATION
[0232] Any of the antibodies and antibody conjugates provided herein can be provided in any appropriate pharmaceutical composition and be administered by any suitable route of administration. Suitable routes of administration include, but are not limited to, the inhalation, intraarterial, intradermal, intramuscular, intraperitoneal, intravenous, nasal, parenteral, pulmonary, and subcutaneous routes.
[0233] The pharmaceutical composition may comprise one or more pharmaceutical excipients. Any suitable pharmaceutical excipient may be used, and one of ordinary skill in the art is capable of selecting suitable pharmaceutical excipients. Accordingly, the pharmaceutical excipients provided below are intended to be illustrative, and not limiting. Additional pharmaceutical excipients include, for example, those described in the Handbook of Pharmaceutical Excipients, Rowe et al. (Eds.) 6th Ed. (2009), incorporated by reference in its entirety.
[0234] In some embodiments, the pharmaceutical composition comprises an anti-foaming agent. Any suitable anti-foaming agent may be used. In some aspects, the anti-foaming agent is selected from an alcohol, an ether, an oil, a wax, a silicone, a surfactant, and combinations thereof. In some aspects, the anti-foaming agent is selected from a mineral oil, a vegetable oil,541107438300\1\AMERICASAttorney Docket No. 108843.00624ethylene bis stearamide, a paraffin wax, an ester wax, a fatty alcohol wax, a long chain fatty alcohol, a fatty acid soap, a fatty acid ester, a silicon glycol, a fluorosilicone, a polyethylene glycol-polypropylene glycol copolymer, polydimethylsiloxane-silicon dioxide, ether, octyl alcohol, capryl alcohol, sorbitan trioleate, ethyl alcohol, 2 -ethyl -hexanol, dimethicone, oleyl alcohol, simethicone, and combinations thereof.
[0235] In some embodiments, the pharmaceutical composition comprises a cosolvent. Illustrative examples of cosolvents include ethanol, poly(ethylene) glycol, butylene glycol, dimethylacetamide, glycerin, and propylene glycol.
[0236] In some embodiments, the pharmaceutical composition comprises a buffer. Illustrative examples of buffers include acetate, borate, carbonate, lactate, malate, phosphate, citrate, hydroxide, diethanolamine, monoethanolamine, glycine, methionine, guar gum, and monosodium glutamate.
[0237] In some embodiments, the pharmaceutical composition comprises a carrier or filler. Illustrative examples of carriers or fillers include lactose, maltodextrin, mannitol, sorbitol, chitosan, stearic acid, xanthan gum, and guar gum.
[0238] In some embodiments, the pharmaceutical composition comprises a surfactant. Illustrative examples of surfactants include t / -alpha tocopherol, benzalkonium chloride, benzethonium chloride, cetrimide, cetylpyridinium chloride, docusate sodium, glyceryl behenate, glyceryl monooleate, lauric acid, macrogol 15 hydroxystearate, myristyl alcohol, phospholipids, polyoxyethylene alkyl ethers, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, polyoxylglycerides, sodium lauryl sulfate, sorbitan esters, and vitamin E polyethylene(glycol) succinate.
[0239] In some embodiments, the pharmaceutical composition comprises an anti-caking agent. Illustrative examples of anti-caking agents include calcium phosphate (tribasic), hydroxymethyl cellulose, hydroxypropyl cellulose, and magnesium oxide.
[0240] Other excipients that may be used with the pharmaceutical compositions include, for example, albumin, antioxidants, antibacterial agents, antifungal agents, bioabsorbable polymers, chelating agents, controlled release agents, diluents, dispersing agents, dissolution enhancers, emulsifying agents, gelling agents, ointment bases, penetration enhancers, preservatives, solubilizing agents, solvents, stabilizing agents, and sugars. Specific examples of each of these agents are described, for example, in the Handbook of Pharmaceutical Excipients, Rowe et al. (Eds.) 6th Ed. (2009), The Pharmaceutical Press, incorporated by reference in its entirety.551107438300\1\AMERICASAttorney Docket No. 108843.00624
[0241] In some embodiments, the pharmaceutical composition comprises a solvent. In some aspects, the solvent is saline solution, such as a sterile isotonic saline solution or dextrose solution. In some aspects, the solvent is water for injection.
[0242] In some embodiments, the pharmaceutical compositions are in a particulate form, such as a microparticle or a nanoparticle. Microparticles and nanoparticles may be formed from any suitable material, such as a polymer or a lipid. In some aspects, the microparticles or nanoparticles are micelles, liposomes, or polymersomes.
[0243] Further provided herein are anhydrous pharmaceutical compositions and dosage forms comprising an antibody or antibody conjugate, since water can facilitate the degradation of some antibodies or conjugates.
[0244] Anhydrous pharmaceutical compositions and dosage forms provided herein can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. Pharmaceutical compositions and dosage forms that comprise lactose and at least one active ingredient that comprises a primary or secondary amine can be anhydrous if substantial contact with moisture and / or humidity during manufacturing, packaging, and / or storage is expected.
[0245] An anhydrous pharmaceutical composition should be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions can be packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e.g., vials), blister packs, and strip packs.13.1. Parenteral Dosage Forms
[0246] In certain embodiments, provided are parenteral dosage forms. Parenteral dosage forms can be administered to subjects by various routes including, but not limited to, subcutaneous, intravenous (including bolus injection), intramuscular, and intraarterial. Because their administration typically bypasses subjects’ natural defenses against contaminants, parenteral dosage forms are typically, sterile or capable of being sterilized prior to administration to a subject. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions.
[0247] Suitable vehicles that can be used to provide parenteral dosage forms are well known to those skilled in the art. Examples include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer’s Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer’s Injection;561107438300\1\AMERICASAttorney Docket No. 108843.00624water miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, com oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
[0248] Excipients that increase the solubility of one or more of the antibodies or antibody conjugates disclosed herein can also be incorporated into the parenteral dosage forms.13.2. Dosage and Unit Dosage Forms
[0249] In human therapeutics, the doctor will determine the posology which he considers most appropriate according to a preventive or curative treatment and according to the age, weight, condition and other factors specific to the subject to be treated.
[0250] In certain embodiments, a composition provided herein is a pharmaceutical composition or a single unit dosage form. Pharmaceutical compositions and single unit dosage forms provided herein comprise a prophylactically or therapeutically effective amount of one or more prophylactic or therapeutic antibodies or antibody conjugates.
[0251] The amount of the antibody or antibody conjugate or composition which will be effective in the prevention or treatment of a disorder or one or more symptoms thereof will vary with the nature and severity of the disease or condition, and the route by which the antibody or antibody conjugate is administered. The frequency and dosage will also vary according to factors specific for each subject depending on the specific therapy (e.g., therapeutic or prophylactic agents) administered, the severity of the disorder, disease, or condition, the route of administration, as well as age, body, weight, response, and the past medical history of the subject. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.
[0252] In certain embodiments, exemplary doses of a composition include milligram or microgram amounts of the antibody or antibody conjugate per kilogram of subject or sample weight (e.g., about 10 micrograms per kilogram to about 50 milligrams per kilogram, about 100 micrograms per kilogram to about 25 milligrams per kilogram, or about 100 microgram per kilogram to about 10 milligrams per kilogram).
[0253] The dose can be administered according to a suitable schedule, for example, once, two times, three times, or four times weekly. It may be necessary to use dosages of the antibody or antibody conjugate outside the ranges disclosed herein in some cases, as will be apparent to those of ordinary skill in the art. Furthermore, it is noted that the clinician or treating physician will know how and when to interrupt, adjust, or terminate therapy in conjunction with subject response.571107438300\1\AMERICASAttorney Docket No. 108843.00624
[0254] Different therapeutically effective amounts may be applicable for different diseases and conditions, as will be readily known by those of ordinary skill in the art. Similarly, amounts sufficient to prevent, manage, treat or ameliorate such disorders, but insufficient to cause, or sufficient to reduce, adverse effects associated with the antibodies or antibody conjugates provided herein are also encompassed by the herein described dosage amounts and dose frequency schedules. Further, when a subject is administered multiple dosages of a composition provided herein, not all of the dosages need be the same.
[0255] In certain embodiments, treatment or prevention can be initiated with one or more loading doses of an antibody or antibody conjugate or composition provided herein followed by one or more maintenance doses.
[0256] In certain embodiments, a dose of an antibody or antibody conjugate or composition provided herein can be administered to achieve a steady-state concentration of the antibody or antibody conjugate in blood or serum of the subject. The steady-state concentration can be determined by measurement according to techniques available to those of skill or can be based on the physical characteristics of the subject such as height, weight and age.
[0257] In certain embodiments, administration of the same composition may be repeated and the administrations may be separated by at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months, or 6 months. In other embodiments, administration of the same prophylactic or therapeutic agent may be repeated and the administration may be separated by at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months, or 6 months.14. THERAPEUTIC APPLICATIONS
[0258] For therapeutic applications, the antibodies and antibody conjugates provided herein are administered to a mammal, generally a human, in a pharmaceutically acceptable dosage form such as those known in the art and those discussed above. For example, the antibodies and antibody conjugates provided herein may be administered to a human intravenously as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intra-cerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, or intratumoral routes. The antibodies or antibody conjugates also are suitably administered by peritumoral, intralesional, or perilesional routes, to exert local as well as systemic therapeutic effects. The intraperitoneal route may be particularly useful, for example, in the treatment of ovarian tumors.
[0259] The antibodies and antibody conjugates provided herein may be useful for the treatment of any disease or condition involving avP6. In some embodiments, the disease or condition is a disease or condition that can be diagnosed by overexpression of avP6. In some 581107438300\1\AMERICASAttorney Docket No. 108843.00624embodiments, the disease or condition is a disease or condition that can benefit from treatment with an anti-avP6 antibody or antibody conjugate. In some embodiments, the disease or condition is a cancer. For examples, the cancer is lung cancer (e.g., Non-Small Cell Lung Cancer (NSCLC)), head and neck cancer (e.g., Head and Neck Squamous Cell Carcinoma (HNSCC)), esophageal cancer (e.g., squamous esophageal cancer), breast cancer, gastric cancer, colorectal cancer, bladder cancer, and pancreatic cancer, skin cancer (e.g., cutaneous squamous cell carcinoma), ovarian cancer, cervical cancer, renal cancer, thyroid cancer, uterine cancer, prostate cancer, cholangiocarcinoma.
[0260] Any suitable cancer may be treated with the antibodies or antibody conjugates provided herein. In some embodiments, the cancer is a solid tumor. Illustrative suitable cancers include, for example, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), adrenocortical carcinoma, anal cancer, appendix cancer, astrocytoma, basal cell carcinoma, brain tumor, bile duct cancer, bladder cancer, bone cancer, breast cancer, bronchial tumor, carcinoma of unknown primary origin, cardiac tumor, cervical cancer, chordoma, colon cancer, colorectal cancer, craniopharyngioma, ductal carcinoma, embryonal tumor, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, fibrous histiocytoma, Ewing sarcoma, eye cancer, germ cell tumor, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, gestational trophoblastic disease, glioma, head and neck cancer, hepatocellular cancer, histiocytosis, Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumor, Kaposi sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, lip and oral cavity cancer, liver cancer, lobular carcinoma in situ, lung cancer, macroglobulinemia, malignant fibrous histiocytoma, melanoma, Merkel cell carcinoma, mesothelioma, metastatic squamous neck cancer with occult primary, midline tract carcinoma involving NUT gene, mouth cancer, multiple endocrine neoplasia syndrome, multiple myeloma, mycosis fungoides, myelodysplastic syndrome, myelodysplastic / myeloproliferative neoplasm, nasal cavity and par nasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-small cell lung cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, papillomatosis, paraganglioma, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytomas, pituitary tumor, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell cancer, renal pelvis and ureter cancer, retinoblastoma, rhabdoid tumor, salivary gland cancer, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, spinal cord tumor, stomach cancer, T-cell lymphoma, teratoid tumor, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, vaginal cancer, vulvar cancer, and Wilms tumor.591107438300\1\AMERICASAttorney Docket No. 108843.00624
[0261] In some embodiments, the disease to be treated with the antibodies or antibody conjugates provided herein is lymphoma, gastric cancer, colorectal cancer, renal cell carcinoma, cervical cancer, lung cancer such as small-cell lung cancer or non-small cell lung carcinoma (e.g., squamous non-small cell lung cancer), ovarian cancer, uterine cancer, endometrial carcinoma, prostate cancer (e.g., metastatic castration-resistant prostate cancer), breast cancer, head and neck cancer, head and neck squamous cell carcinoma, esophageal cancer (e.g., esophageal squamous cell carcinoma), urothelial cancer, brain carcinoma, liver cancer, pancreatic cancer, mesothelioma, bladder cancer, melanoma, and / or a cancer of epithelial origin. In particular embodiments, the disease is colorectal cancer. In some embodiments, the disease is ovarian cancer. In some embodiments, the disease is breast cancer. In some embodiments, the disease is lung cancer. In some embodiments, the disease is head and neck cancer. In some embodiments, the disease is renal cell carcinoma. In some embodiments, the disease is brain carcinoma. In some embodiments, the disease is endometrial carcinoma. In some embodiments, the disease is a cancer is selected from lymphoma, metastatic castration-resistant prostate cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, squamous non-small cell lung cancer, urothelial cancer, lung cancer, breast cancer, prostate cancer, small-cell lung cancer, bladder cancer, and melanoma.15. DIAGNOSTIC APPLICATIONS
[0262] In some embodiments, the antibodies or antibody conjugates provided herein are used in diagnostic applications. For example, an anti-avP6 antibody or antibody conjugate may be useful in assays for avP6 protein. In some aspects, the antibody or antibody conjugate can be used to detect the expression of avP6 in various cells and tissues. These assays may be useful, for example, in making a diagnosis and / or prognosis for a disease, such as a cancer.
[0263] In some diagnostic and prognostic applications, the antibody or antibody conjugate may be labeled with a detectable moiety. Suitable detectable moieties include, but are not limited to radioisotopes, fluorescent labels, and enzyme-substrate labels. In another embodiment, the anti-avP6 antibody or antibody conjugate need not be labeled, and the presence of the antibody or antibody conjugate can be detected using a labeled antibody which specifically binds to the anti-avP6 antibody.16. AFFINITY PURIFICATION REAGENTS
[0264] The antibodies or antibody conjugates provided herein may be used as affinity purification agents. In this process, the antibodies or antibody conjugates may be immobilized on a solid phase such as resin or filter paper, using methods well known in the art. The601107438300\1\AMERICASAttorney Docket No. 108843.00624immobilized antibody or antibody conjugate is contacted with a sample containing the avP6 protein (or fragment thereof) to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the avP6 protein, which is bound to the immobilized antibody or antibody conjugate. Finally, the support is washed with another suitable solvent, such as glycine buffer, pH 5.0 that will release the avP6 protein from the antibody or antibody conjugate.17. KITS
[0265] In some embodiments, an anti-avP6 antibody or antibody conjugate provided herein is provided in the form of a kit, i.e., a packaged combination of reagents in predetermined amounts with instructions for performing a procedure. In some embodiments, the procedure is a diagnostic assay. In other embodiments, the procedure is a therapeutic procedure.
[0266] In some embodiments, the kit further comprises a solvent for the reconstitution of the anti-avP6 antibody or antibody conjugate. In some embodiments, the anti-avP6 antibody or antibody conjugate is provided in the form of a pharmaceutical composition. In some embodiments, the anti-avP6 antibody or antibody conjugate is provided in a lyophilized form.EXAMPLES EXAMPLE 1: GENERATION OF ANTI-av|J6 ANTIBODIESPhage display selections
[0267] Antibody Fab libraries were constructed using a Trastuzumab Fab sequence codon optimized for XpressCF® in a modified, commercially available p3 phagemid vector (Antibody Design Labs). The phagemid vector was modified to express Fab heavy chains as C-terminal p3 fusion proteins, and regulatory regions (start codons, restriction enzyme sites, periplasmic leader sequences) were optimized for Fab display levels. Libraries were constructed using standard overlap extension PCR protocols with mutagenic primers targeting heavy chain complementary determining regions (CDRs) and rescued through electroporation in M13-K07 infected SS320 E. coli cells. See, Heckman and Pease, Nat. Protoc., 2007, 2:924-932; Rajan, S. & Sidhu, S. S., Methods Enzymol., 2012, 502:3-23, both incorporated by reference in their entireties. Library selections were performed using standard phage display protocols. See Marks, J. D. & Bradbury, A., Methods Mol. Biol., 2004, 248:161-76; Rajan, S. & Sidhu, S. S., Methods Enzymol., 2012, 502:3-23; Barbas II, CF & Burton, DR, Phage Display: A Laboratory Manual (2001), Cold Spring Harbor Laboratory Press, each of which is incorporated herein by reference in its entirety. Following multiple selection rounds against recombinant human (AcroBiosystems, cat. # IT6-611107438300\1\AMERICASAttorney Docket No. 108843.00624H52E1) or cyno (AcroBiosystems, cat. # IT6-C52W9) avP6 heterodimer, Fab heavy chain pools were transferred into cell-free expression vectors for expression as His6 and FLAG-tagged IgGl.High throughput cell free expression and FACS based screening of selection outputs
[0268] Libraries of antibody variants generated by selection workflow were transformed into E. coli and grown on agar plates with antibiotic (kanamycin). Individual colonies were grown in liquid broth (TB + kanamycin) and used as a template for DNA amplification via rolling circle amplification (RCA). The variants were then expressed in cell-free protein synthesis reactions as described in Zawada et al., BiotechnoL Bioeng., 2011, 108:1570-1578 and Cai, et al., Biotechnol. Prg., 2015, 823-831, each of which is incorporated by reference in its entirety.
[0269] Briefly, cell-free extracts were treated with 50 pM iodoacetamide for 30 minutes at room temperature (approximately 20°C) and added to a premix containing cell-free components (see Groff et al., mAbs, 2014, 6:671-678 and Cai et al., Biotechnol. Prg., 2015, 823-831, each of which is incorporated by reference in its entirety) and 10% (v / v) RCA DNA template (approximately 10 pg / mL DNA) for HC variants of interest, in addition to 300ug / mL purified Trastuzumab LC which is present for antibody assembly but is not varied in the library. Trastuzumab LC was not added to cell-free reactions for scFvFc libraries. One hundred microliters of cell-free reactions were incubated at 30°C for 12 hours on a shaker at 650 rpm in 96-well plates.
[0270] To identify antibodies that bind to human avP6, primary FACS screens were conducted using a HEK293 -human avP6 (havP6) overexpression cell line with parental HEK293 cells serving as the negative cell line. Cells were maintained in DMEMZF12 1-1 (Corning) supplemented with 10% heat-inactivated fetal bovine serum (Sigma), 2 mM Glutamax (Thermo Scientific), and IX Penicillin / Streptomycin (Corning). Parental HEK293 cells were stained with CellTrace Oregon Green 488 (Invitrogen) and washed twice with ice-cold FACS buffer (DMEMZF12 + 10% FBS). 50,000 Oregon Green stained HEK293 and 50,000 unstained HEK293-havP6 cells were added to each well and incubated on ice for one hour with cell free reactions diluted 50-fold in FACS buffer. Samples were washed twice and incubated with 3 pg / mL AlexaFluor 647-labeled donkey anti-human Fc antibody (Jackson ImmunoResearch) on ice for 1 hour. Samples were washed twice with ice-cold FACS buffer and analyzed using a FACSCanto II flow cytometer (BD Biosciences). Fluorescence was measured in both the FITC and APC-A channels. Binding for each sample was reported as a ratio of the APC-A geometric mean fluorescence intensity of FITC negative cells relative to APC-A signal of FITC positive cells. Four hundred to one-thousand-two-hundred colonies were screened, depending on the predicted diversity of different selection campaigns.621107438300\1\AMERICASAttorney Docket No. 108843.00624Secondary screening of av 6 antibody variants
[0271] The selected candidates from the initial round of screening were cultured and miniprepped via the Qiaprep 96 Turbo miniprep kit (Qiagen) according to manufacturer’s instructions. 5 pg / mL miniprepped HC DNA and either 5 pg / mL of LC DNA or 300 pg / mL Trastuzumab LC were added to 4 mL cell-free reactions and incubated overnight for 12 hours at 30°C, 650 rpm. Expressed variants from clarified cell-free reactions were purified via protein A purification using a semi -automated high throughput batch purification method. Briefly, purifications were performed in a 96-well plate format where 25 pL / well of resin ( Mab Select Sure, Cytiva) was equilibrated in PBS, incubated with 1 mL cell-free reaction for 15 minutes followed by one wash each of PBS, arginine wash buffer (50 mM potassium phosphate, 800 mM L-arginine, pH 7.0) and 300 mM NaCl. Antibody variants were then eluted using 200 pL elution buffer (100 mM citrate, 300 mM L-arginine, pH 3.0) and buffer exchanged into PBS using a 96-well Zeba plate (7 kD MWCO, Thermofisher). Purified antibodies were quantified via high throughput capillary electrophoresis using the Labchip GXII (Perkin Elmer) against a Herceptin standard curve, according to manufacturer’s instructions.Thermal stability analysis
[0272] A protein thermal shift assay was carried out by mixing the antibody to be assayed with an environmentally sensitive dye (SYPRO Orange, Life Technologies, cat. #S-6650) in a phosphate buffered solution (PBS), and monitoring the fluorescence of the mixture in real time as it underwent controlled thermal denaturation. Protein solutions between 0.2-2 mg / mL were mixed at a 1-1 volumetric ratio with a 1-250 PBS-diluted solution of SYPRO Orange (SYPRO Orange stock dye is 5000X in DMSO). 6 pL aliquots of the protein-dye mixture were dispensed in quadruplicate in a 384-well microplate (Bio-Rad, cat. # MSP-3852), and the plate was sealed with an optically clear sealing film (Bio-Rad, cat. #MSB-1001) and placed in a 384-well plate real-time thermocycler (Bio-Rad CFX384 Real Time System). The protein-dye mixture was heated from 25°C to 95°C, at increments of 0.2°C per cycle (~1.5°C per minute), allowing 3 seconds of equilibration at each temperature before taking a fluorescence measurement. At the end of the experiment, the transition melting temperatures (TM1 and TM2) were determined using the Bio-Rad CFX manager software. TM1 represents the melting temperature of the Fc domain. TM2 represents the melting temperature of the Fab domain. Selected antibodies exhibited a TM1 > 50°C and a TM2 > 60°C, and certain antibodies had a TM1 > 60°C and a TM2 > 70°C.
[0273] The results are shown in Table 5.Table 5: av 6 antibody thermal stability631107438300\1\AMERICASAttorney Docket No. 108843.00624641107438300\1\AMERICASAttorney Docket No. 108843.00624651107438300\1\AMERICASAttorney Docket No. 108843.00624661107438300\1\AMERICASAttorney Docket No. 108843.00624671107438300\1\AMERICASAttorney Docket No. 108843.00624681107438300\1\AMERICASAttorney Docket No. 108843.00624av 6 Antibody Epitope Binning
[0274] All test antibodies were amine-coupled in an array format onto a CDM200 chip on a Carterra LSA instrument using standard EDC / NHS chemistry. Binning experiments were performed in HBSN buffer (Cytiva) supplemented with 1 mM MgCE and 1 mM CaCk Each cycle included a baseline stabilization, capture of human avP6 (Aero Biosystems), measurement of second antibody binding, and regeneration.
[0275] Human avP6 was captured by injecting at 200 nM for 5 minutes. Subsequently, a test antibody was flowed over the surface at 100 nM for 5 minutes to assess binding to the captured antigen. Regeneration was achieved by two consecutive 30-second injections of 10 mM glycine, pH 2.0, to dissociate bound avP6.
[0276] Each test antibody was evaluated individually, and buffer blanks were run prior to every 10th cycle for quality control. Data were analyzed using Carterra Epitope software vl.9.2.4505, with reference subtraction and Y-alignment to the baseline. Antibodies were classified as binding distinct (non-overlapping) epitopes if the binding response of the second antibody exceeded that of buffer blanks and / or the self-binning response of the immobilized antibody, as shown in Table 6.Table 6: Epitope binning of av 6 antibodies*The control antibody is the anti-avP6 antibody as described in Lyon RP et al., Mol Cancer Ther.2023 Aug 24;22(12): 1444-1453, which is incorporated by reference in its entirety.
[0277] Non-natural amino acids were introduced to the heavy chains of the antibodies in a site-specific manner. Non-natural amino acids and incorporation sites in exemplary antibodies are shown in Table 7.Table 7.691107438300\1\AMERICASAttorney Docket No. 108843.00624Synthetic libraries and characterization:
[0278] Integrin-P6 can exclusively heterodimerize with integrin-aV. Recombinant ITGaV / ITGB6 heterodimeric complex can adopt multiple structural conformations, including bend-closed, extended closed, and extended open. As a consequence, the complex can be challenging to obtain consistent results from when used in assays such as Biacore / SPR or ELISA. To circumvent this issue, outputs from multiple synthetic antibody library selections against ITGaV / ITGB6 were screened for candidates using high-throughput FACS. Hits of interest were evaluated for properties, including internalization, cross-reactivity with cynomolgus ITGaV / ITGB6, specificity for ITGB6, expression titer, cell binding and secondary cell killing on SW780 cells, and sequence diversity. Eleven antibody candidates with favorable human / cynomolgus cross-reactivity, internalizing activity, and favorable ITGB6 specificity were affinity matured and subjected to a second round of screening, from which four candidates with favorable PK properties (based on 7-day PK screen) and manufacturability data were identified. Four candidate IgGs were further evaluated for full PK profile in TG32 mice and efficacy in mouse models.EXAMPLE 2: LAP LIGAND COMPETITION ASSAY
[0279] avP6 antibodies were tested whether they compete with LAP for binding to avP6 using an ELISA-based assay. A 96-well white flat bottom maxisorp plate was coated with 0.3 pg / mL LAP (AcroBiosystems, cat. # C947P1-219AFI-179) overnight at 4°C in 1XPBS supplemented with 1 mM MgCL and 1 mM CaCL. Antibodies at 200 nM starting concentrations were serially diluted 4-fold seven times and incubated with 10 nM human avP6 (Sino Biological, cat. # LC17A0103) in Buffer A (50 mM Tris, pH 7.5, 150 mM NaCl, 1 mg / mL BSA, 1 mM MgCh, 1 mM CaCL) overnight at 4°C. The next day the plate was washed three times with 0.1%701107438300\1\AMERICASAttorney Docket No. 108843.00624Tween-20 in 1XPBS (PBST) containing 1 mM MgCh and 1 mM CaCh. Afterwards the plate was blocked in PBST with 2% BSA, 1 mM MgCh, and 1 mM CaCh for 1 hour at 25°C with gentle shaking and then washed three times with PBST. The preformed avP6-antibody complexes were added to the plate and incubated for 1 hour at 25°C with gentle shaking. The plate was subsequently washed three times with PBST. HRP-conjugated anti-human Fc antibody (Jackson Immunoresearch, cat. # 109-035-098) was diluted 1:10,000 in Buffer A and incubated on the plate for 1 hour at 25°C with gentle shaking. The plate was then washed three times with PBST. Supersignal Pico Chemiluminescent Substrate (ThermoFisher Scientific, cat. #37069) was added to the plate, and HRP-produced signal was read using a SpectraMax M5 Microplate Reader (Molecular Devices). As shown in Table 8, antibodies were determined to be blocking or non-blocking for LAP binding to avP6 based on their plotted binding curves (GraphPad Prism, GraphPad Software) and whether at the highest concentration signal exceeded a Trastuzumab control by greater than 2-fold.Table 8: avp6 binding to LAP with avp6 antibodiesEXAMPLE 3. INTERNALIZATION ACTIVITY MEASURED BY 2NDADC CELL KILLING ASSAY
[0280] The internalization ability of the antibodies was evaluated by 2ndADC cell killing assay on target positive SW780 cells. SW780 cells were obtained from ATCC and maintained in All solid tumor cell lines were maintained in DMEM / F12 (1:1), high glucose (Corning) supplemented with 10% heat inactivated FBS (Sigma), 2mM Glutamax (ThermoFisher Scientific), and lx Penicillin / Streptomycin (Corning). Cancer cells were harvested using Accutase® (Innovative Cell Technologies), counted by the Vi-CELL Cell Viability Analyzers (Beckman Coulter). A total of 625 cells in a volume of 25 ul were seeded in each well of a 384-711107438300\1\AMERICASAttorney Docket No. 108843.00624well flat bottom white polystyrene plate. Lead antibodies were formulated at 4x starting concentration in the cell culture medium and filtered through Multi Screenurs 96-Well Filter Plates (Millipore). 12.5ul of the serial diluted antibody was added into treatment wells and 12.5ul of Anti-hFc-hemiasterlin (hemiasterlin as described in WO2016123582, which is incorporated by reference herein in its entirety) nanobody was then added into each well at a fixed final concentration of 20nM. Assay plates were cultured at 37°C in a CO2 incubator for 120hrs before the assay. For cell viability measurement, 30pl of Cell Titer-Gio® reagent (Promega Corp. Madison, WI) was added into each well, and plates were processed as per product instructions. Relative luminescence was measured on an ENVISION® plate reader (Perkin-Elmer; Waltham, MA). Relative luminescence readings were converted to % viability using untreated cells as controls. Data was fitted with non-linear regression analysis, using log(inhibitor) vs. response -variable slope, 4 parameter fit equation using GraphPad Prism (GraphPad Inc.). Cell killing EC50(nM) and span (%) was reported using GraphPad Prism. The results are shown in Tables 9 and 10.Table 9Table 10721107438300\1\AMERICASAttorney Docket No. 108843.00624EXAMPLE 4. AVB6 BINDING OF GENERATED ANTIBODIESFACS-based Cell Binding
[0281] The binding activity of the avP6 antibodies were examined in a FACS based cell binding assay. HEK293T and HeLa cells were purchased from ATCC (American Type Culture Collection). HEK293 cells were transfected to stably express human ITGB6 (hITGB6), or human ITGB1 (hITGBl), or human ITGB3 (hITGB3), or human ITGB5 (hITGB5), or human 731107438300\1\AMERICASAttorney Docket No. 108843.00624ITGB8 (hITGB8), or mouse ITGB6 (mITGB6), or rat ITGB6 (rITGB6) on cell surface. HeLA cells were transfected to stably express cyno ITGB6 (cITGB6) on the cell surface. Parental and engineered cells were harvested with accutase (Hyclone) and suspended in FACS buffer (DPBS buffer supplemented with 1% bovine serum albumin). A total of 200,000 cells per sample were incubated on ice for 60 minutes with lOOnM of anti-ITGB6 antibodies. Cells were washed twice with ice-cold FACS buffer and incubated with 5ug / ml Alexa-647 labeled goat anti-human Fey antibody (Jackson ImmunoResearch Laboratories) on ice for another 60 minutes. Unstained cells and secondary antibody were used as controls. Cells were then washed twice with staining buffer and plates were read on the Attune NxT flow cytometer (Thermo Scientific). Geometric Median fluorescence intensities (MFI) were obtained using Flowjo software. Using GraphPad Prism, data was plotted with MFI as Y-axis and antibody concentration in nanomolar (nM) as X-axis and fitted using non-linear regression analysis with one site specific binding equation. Bmax and Kd were reported by GraphPad Prism.
[0282] As shown in Tables 11A-11B, 12, 13 and 14A-14B, the representative avP6 antibodies bind to human and cyno ITGB6 with high affinity, some also show cross-reactivity to mouse ITGB6. None of the antibodies showed any binding to other integrin family members such as ITGB1, ITGB3, ITGB5 or ITGB8.Table 11A avP6 antibodies cell binding Bmax and KdTable 11B avP6 antibodies cell binding Bmax and KdTable 12 avP6 antibodies cell binding Bmax and Kd741107438300\1\AMERICASAttorney Docket No. 108843.00624Table 13 avP6 antibodies cell binding Bmax and Kd751107438300\1\AMERICASAttorney Docket No. 108843.00624761107438300\1\AMERICASAttorney Docket No. 108843.00624Table 14A avP6 antibodies cell binding Bmax and KdNB=No BindingTable 14B avP6 antibodies cell binding Bmax and KdNB=No BindingEXAMPLE 4: EFFECT OF ANTI-AVB6 ANTIBODIES ON TGF-BETA SIGNAL PATHWAY
[0283] Transforming growth factor P (TGF P) family members are secreted as inactive complexes with a latency -associated peptide (LAP), which is a ligand for avP6. When avP6 is binding to LAP, the TGFp is released from the LAP and can then activate the downstream signal transduction. The ability of anti-ITGp6 antibodies to inhibit TGF-P signal was also assessed using a cell -based TGF-P reporter system.771107438300\1\AMERICASAttorney Docket No. 108843.00624
[0284] Shmac4 cells were purchased from ATCC (American Type Culture Collection). HEK-blue-TGF-P reporter cells were purchased from Invivogen. The day before the assay, 15,000 Shmac4 cells and 2K HEK-blue-TGF-b reporter cells in 40uL of assay medium were plated into each well of a 96-well plate. The assay medium is Keratinocyte basal medium 2 (Sigma C-20211) supplemented with Keratinocyte Growth Supplement pack (Sigma C-39011), 2 mM Glutamine and 2% Fetal Bovine Serum (FBS). In a separated 96-well plate, 15,000 HEK293T cells and 2K HEK-blue-TGF-b reporter cells in 40uL of assay medium were plated as negative controls. Serial diluted test articles in lOul of assay medium were added into the 96-well plates. After incubation of the assay plates at 37°C incubator with 5% CO2 for two days, 40ul of the cell-culture medium from each well was transferred to a clear 96-well half area plate. For the assay readout, 60ul of QU ANTI Blue™ Solution with SEAP substrate was added to each well of the 96-well half area plate. After incubation overnight at 37°C incubator with 5% CO2, the absorbance at 630nm was measured with a M5 Spectramax instrument (Molecular Devices). Data was converted to % of control using untreated wells as control and fitted with non-linear regression analysis, using a log(inhibitor) vs. response-variable slope, 4-parameter fit with GraphPad Prism.
[0285] In this assay, human LAP protein was added as positive control. Free LAP can bind to ITGB6 and result in a stable latent LAP-TGF-P complex. As shown in FIG. 2, free LAP inhibited the TGB-P signal as expected. Anti-avP6 antibodies from 3850 family showed similar inhibitory activity as LAP, while 3783-D04 did not affect the TGB-b pathway.Table 15 avP6 antibodies effect on TGF-P pathwayNA=Not ActiveEXAMPLE 5: LIVE IMAGING-BASED INTERNALIZATION ASSAY
[0286] HCC38 cells were purchased from ATCC (American Type Culture Collection) and maintained in DMEM / F12 (1:1), high glucose (Corning) supplemented with 10% heat-inactivated fetal bovine serum (Sigma), 2mM glutamax (Thermo Scientific), and lx781107438300\1\AMERICASAttorney Docket No. 108843.00624Penicillin / Streptomycin (Coming). To measure the internalization activity, the avP6 antibodies was labeled with DBCO-pHrodo red dye. The day before the assay, HCC38 cells were plated at 3000 cell / well in flat clear bottom 96-well plates and incubated overnight at 37°C in a CO2 incubator. Serial -dilute pHrodo Red- samples were added into wells containing the HCC38 and the plates were incubated for 72 hrs in Incucyte (Sartorius) Live-Cell Imaging system with fluorescent images captured every 2hrs. The images were analyzed by Live-Cell Analysis software and internalization data plotted as % of (red area) / (phase area) overtime.
[0287] All four anti-avP6 antibodies tested in the assay internalized quickly into HCC38 cells within 2 hrs and reached a plateau of 25%-30% around 24hrs. An isotype control IgGl conjugated to the same pHrodo dye did not show any internalization. The results are shown in FIG. 3A
[0288] Another internalization assay was performed for antibody 11, the control antibody described in Table 6 and isotype control antibody using anti-Fc antibody labeled with pHrodo. As shown in FIG. 3B, Antibody 11 showed a high final percentage of internalization compared to the control antibody.Table 16 provides sequences referred to herein.Table 16. Sequence Table791107438300\1\AMERICASAttorney Docket No. 108843.00624801107438300\1\AMERICASAttorney Docket No. 108843.00624811107438300\1\AMERICASAttorney Docket No. 108843.00624821107438300\1\AMERICASAttorney Docket No. 108843.00624831107438300\1\AMERICASAttorney Docket No. 108843.00624841107438300\1\AMERICASAttorney Docket No. 108843.00624851107438300\1\AMERICASAttorney Docket No. 108843.00624861107438300\1\AMERICASAttorney Docket No. 108843.00624871107438300\1\AMERICASAttorney Docket No. 108843.00624881107438300\1\AMERICASAttorney Docket No. 108843.00624891107438300\1\AMERICASAttorney Docket No. 108843.00624901107438300\1\AMERICASAttorney Docket No. 108843.00624911107438300\1\AMERICASAttorney Docket No. 108843.00624921107438300\1\AMERICASAttorney Docket No. 108843.00624931107438300\1\AMERICASAttorney Docket No. 108843.00624941107438300\1\AMERICASAttorney Docket No. 108843.00624951107438300\1\AMERICASAttorney Docket No. 108843.00624961107438300\1\AMERICASAttorney Docket No. 108843.00624971107438300\1\AMERICASAttorney Docket No. 108843.00624981107438300\1\AMERICASAttorney Docket No. 108843.00624991107438300\1\AMERICASAttorney Docket No. 108843.006241001107438300\1\AMERICASAttorney Docket No. 108843.006241011107438300\1\AMERICASAttorney Docket No. 108843.006241021107438300\1\AMERICASAttorney Docket No. 108843.006241031107438300\1\AMERICASAttorney Docket No. 108843.006241041107438300\1\AMERICASAttorney Docket No. 108843.006241051107438300\1\AMERICASAttorney Docket No. 108843.006241061107438300\1\AMERICASAttorney Docket No. 108843.006241071107438300\1\AMERICASAttorney Docket No. 108843.006241081107438300\1\AMERICASAttorney Docket No. 108843.006241091107438300\1\AMERICASAttorney Docket No. 108843.006241101107438300\1\AMERICASAttorney Docket No. 108843.00624Ill1107438300\1\AMERICASAttorney Docket No. 108843.006241121107438300\1\AMERICASAttorney Docket No. 108843.006241131107438300\1\AMERICASAttorney Docket No. 108843.006241141107438300\1\AMERICASAttorney Docket No. 108843.006241151107438300\1\AMERICASAttorney Docket No. 108843.006241161107438300\1\AMERICASAttorney Docket No. 108843.006241171107438300\1\AMERICASAttorney Docket No. 108843.006241181107438300\1\AMERICASAttorney Docket No. 108843.006241191107438300\1\AMERICASAttorney Docket No. 108843.006241201107438300\1\AMERICASAttorney Docket No. 108843.006241211107438300\1\AMERICASAttorney Docket No. 108843.006241221107438300\1\AMERICASAttorney Docket No. 108843.00624EQUIVALENTS
[0289] The disclosure set forth above may encompass multiple distinct inventions with independent utility. Although each of these inventions has been disclosed in its preferred form(s), the specific embodiments thereof as disclosed and illustrated herein are not to be considered in a limiting sense, because numerous variations are possible. The subject matter of the inventions includes all novel and nonobvious combinations and subcombinations of the various elements, features, functions, and / or properties disclosed herein. The following claims particularly point out certain combinations and subcombinations regarded as novel and nonobvious. Inventions embodied in other combinations and subcombinations of features, functions, elements, and / or properties may be claimed in this application, in applications claiming priority from this application, or in related applications. Such claims, whether directed to a different invention or to the same invention, and whether broader, narrower, equal, or different in scope in comparison to the original claims, also are regarded as included within the subject matter of the inventions of the present disclosure.
[0290] One or more features from any embodiments described herein or in the figures may be combined with one or more features of any other embodiments described herein or in the figures without departing from the scope of the invention.
[0291] All publications, patents and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.1231107438300\1\AMERICAS
Claims
1. Attorney Docket No. 108843.00624WHAT IS CLAIMED IS:
1. An isolated antibody that specifically binds to Integrin avP6 (avP6), wherein the antibody comprises three heavy chain CDRs from a VH sequence selected from SEQ ID NOs: 1373, 1406, 1407, 1408, 1424, 1464, 1474, 1487, 1488, 1489, and 1491, or variants thereof, and three light chain CDRs from a VL sequence selected from SEQ ID NO: 1495, or variants thereof.
2. The isolated antibody of claim 1, wherein the antibody comprises a CDR-H3, a CDR- H2, CDR-H1, a CDR-L3, a CDR-L2, and a CDR-L1 of a VH- VLpair selected from the group consisting of SEQ ID NOs: 1373 / 1495, 1406 / 1495, 1407 / 1495, 1408 / 1495, 1424 / 1495, 1464 / 1495, 1474 / 1495, 1487 / 1495, 1488 / 1495, 1489 / 1495, and 1491 / 1495.
3. The isolated antibody of claim 2, wherein the antibody comprises six CDRs selected from the group consisting of SEQ ID NOs: 381 / 877 / 1125 / 1492 / 1493 / 1494;414 / 910 / 1158 / 1492 / 1493 / 1494; 415 / 911 / 1159 / 1492 / 1493 / 1494;416 / 912 / 1160 / 1492 / 1493 / 1494; 432 / 928 / 1176 / 1492 / 1493 / 1494;472 / 968 / 1216 / 1492 / 1493 / 1494; 482 / 978 / 1226 / 1492 / 1493 / 1494;495 / 991 / 1239 / 1492 / 1493 / 1494; 496 / 992 / 1240 / 1492 / 1493 / 1494;497 / 993 / 1241 / 1492 / 1493 / 1494; and 499 / 995 / 1243 / 1492 / 1493 / 1494.
4. The isolated antibody of claim 2, wherein the antibody comprises six CDRs selected from the group consisting of SEQ ID NOs: 133 / 629 / 1125 / 1492 / 1493 / 1494, 166 / 662 / 1158 / 1492 / 1493 / 1494, 167 / 663 / 1159 / 1492 / 1493 / 1494, 168 / 664 / 1160 / 1492 / 1493 / 1494, 184 / 680 / 1176 / 1492 / 1493 / 1494, 224 / 720 / 1216 / 1492 / 1493 / 1494, 234 / 730 / 1226 / 1492 / 1493 / 1494, 247 / 743 / 1239 / 1492 / 1493 / 1494, 248 / 744 / 1240 / 1492 / 1493 / 1494, 249 / 745 / 1241 / 1492 / 1493 / 1494, and 251 / 747 / 1243 / 1492 / 1493 / 1494.
5. The isolated antibody of any one of preceding claims, wherein the antibody comprises a VH sequence selected from SEQ ID NOs: 1373, 1406, 1407, 1408, 1424, 1464, 1474, 1487, 1488, 1489, and 1491; anda VL sequence set forth in SEQ ID NO: 1495.1241107438300\1\AMERICASAttorney Docket No. 108843.006246. The isolated antibody of any one of preceding claims, wherein the antibody comprises a heavy chain sequence selected from SEQ ID NOs: 1497-1511, and an LC sequence set forth in SEQ ID NO: 1496.
7. The isolated antibody of claim 1, wherein the antibody comprises three heavy chain CDRs from the VH sequence set forth in SEQ ID NO: 1373 and three light chain CDRs from a VL sequence selected from SEQ ID NO: 1495.
8. The isolated antibody of claim 7, wherein the antibody comprises a CDR-H3, a CDR- H2, CDR-H1, a CDR-L3, a CDR-L2, and a CDR-L1 of a VH- VLpair set forth in SEQ ID NOs: 1373 / 1495.
9. The isolated antibody of claim 7, wherein the antibody comprises six CDRs set forth in 381 / 877 / 1125 / 1492 / 1493 / 1494.
10. The isolated antibody of claim 7, wherein the antibody comprises six CDRs set forth in 133 / 629 / 1125 / 1492 / 1493 / 1494.
11. The isolated antibody of claim 7, wherein the antibody comprises a VH / VL pair set forth in SEQ ID NO: 1373 / 1495.
12. The isolated antibody of claim 7, wherein the antibody comprises a heavy chain / light chain pair set forth in SEQ ID NOs: 1511 / 1496.
13. The isolated antibody of claim 7, wherein the antibody comprises a heavy chain / light chain pair set forth in SEQ ID NOs: 1507 / 1496.
14. The isolated antibody of claim 1, wherein the antibody comprises three heavy chain CDRs from the VH sequence set forth in SEQ ID NO: 1487 and three light chain CDRs from a VL sequence selected from SEQ ID NO: 1495.
15. The isolated antibody of claim 14, wherein the antibody comprises a CDR-H3, a CDR- H2, CDR-H1, a CDR-L3, a CDR-L2, and a CDR-L1 of a VH - VL pair set forth in SEQ ID NOs: 1487 / 1495.1251107438300\1\AMERICASAttorney Docket No. 108843.0062416. The isolated antibody of claim 14, wherein the antibody comprises six CDRs set forth in 495 / 991 / 1239 / 1492 / 1493 / 1494.
17. The isolated antibody of claim 14, wherein the antibody comprises six CDRs set forth in 247 / 743 / 1239 / 1492 / 1493 / 1494.
18. The isolated antibody of claim 14, wherein the antibody comprises a VH / VL pair set forth in SEQ ID NO: 1487 / 1495.
19. The isolated antibody of claim 14, wherein the antibody comprises a heavy chain / light chain pair set forth in SEQ ID NOs: 1503 / 1496.
20. The isolated antibody of claim 14, wherein the antibody comprises a heavy chain / light chain pair set forth in SEQ ID NOs: 1510 / 1496.
21. The isolated antibody of claim 1, wherein the antibody comprises three heavy chain CDRs from the VH sequence set forth in SEQ ID NO: 1406 and three light chain CDRs from a VL sequence selected from SEQ ID NO: 1495.
22. The isolated antibody of claim 21, wherein the antibody comprises a CDR-H3, a CDR- H2, CDR-H1, a CDR-L3, a CDR-L2, and a CDR-L1 of a VH- VLpair set forth in SEQ ID NOs: 1406 / 1495.
23. The isolated antibody of claim 21, wherein the antibody comprises six CDRs set forth in 414 / 910 / 1158 / 1492 / 1493 / 1494.
24. The isolated antibody of claim 21, wherein the antibody comprises six CDRs set forth in 166 / 662 / 1158 / 1492 / 1493 / 1494.
25. The isolated antibody of claim 21, wherein the antibody comprises a VH / VL pair set forth in SEQ ID NO: 1406 / 1495.
26. The isolated antibody of claim 21, wherein the antibody comprises a heavy chain / light chain pair set forth in SEQ ID NOs: 1497 / 1496.1261107438300\1\AMERICASAttorney Docket No. 108843.0062427. The isolated antibody of claim 21, wherein the antibody comprises a heavy chain / light chain pair set forth in SEQ ID NOs: 1508 / 1496.
28. The isolated antibody of any one of preceding claims, wherein the antibody inhibits binding of a second antibody to avP6 by at least 50%, or wherein the second antibody inhibits binding of the isolated antibody to avP6 by at least 50%.
29. The isolated antibody of any one of preceding claims, wherein the antibody is a monoclonal antibody.
30. The isolated antibody of any one of preceding claims, wherein the antibody is an IgA, an IgD, an IgE, an IgG, or an IgM.
31. The isolated antibody of any one of preceding claims, wherein the antibody is humanized or human.
32. The isolated antibody of any one of preceding claims, wherein the antibody is aglycosylated.
33. The isolated antibody of any one of preceding claims, wherein the antibody is an antibody fragment.
34. The isolated antibody of claim 33, wherein the antibody fragment is selected from an Fv fragment, a Fab fragment, a F(ab’)2 fragment, a Fab’ fragment, an scFv (sFv) fragment, and an scFv-Fc fragment.
35. The isolated antibody of any one of preceding claims, wherein the antibody has a kaof about 103M^xsec'1to about 106M^xsec'1when associating with human avP6 at a temperature of 25°C.
36. The isolated antibody of any one of preceding claims, wherein the antibody has a ka of about 10'4sec'1to about 10'8sec'1when dissociating from human avP6 at a temperature of25°C.
37. The isolated antibody of any one of preceding claims, wherein the antibody has a KD of about 10'7M to about 10'12M when bound to human avP6 at a temperature of 25°C.1271107438300\1\AMERICASAttorney Docket No. 108843.0062438. The isolated antibody of any one of preceding claims, further comprising human framework regions.
39. The isolated antibody of any one of claims 1-38, further comprising human kappa framework regions.
40. The isolated antibody of any one of preceding claims, comprising a heavy chain comprising a CH2 domain with an amino acid substitution of V264S.
41. An isolated antibody that specifically binds to an epitope consisting of the sequence set forth in the same epitope as the epitope of the isolated antibody of any one of preceding claims.
42. A kit comprising an isolated antibody of any of the preceding claims, and instructions for use of the antibody.
43. The kit of claim 42, wherein the antibody is lyophilized.
44. The kit of claim 43, further comprising a fluid for reconstitution of the lyophilized antibody.
45. A polynucleotide encoding an isolated antibody of any of claims 1 to 41.
46. A vector comprising the polynucleotide of claim 45.
47. A recombinant host cell comprising the vector of claim 46.
48. The recombinant host cell of claim 47, wherein the host cell is selected from a bacterial cell, a fungal cell, and a mammalian cell.
49. The recombinant host cell of claim 48, wherein the host cell is selected from an E. coli cell, a Saccharomyces cerevisiae cell, and a CHO cell.
50. A cell-free expression reaction comprising the vector of claim 46.1281107438300\1\AMERICASAttorney Docket No. 108843.0062451. An antibody conjugate comprising an isolated antibody of any one of claims 1-41 linked to at least one payload optionally via a linker.
52. The antibody conjugate of claim 51, wherein the at least one payload is a cytotoxic payload.
53. A pharmaceutical composition comprising the antibody of any one of claims 1 to 41, or the antibody conjugate of any one of claims 51 to 52 and a pharmaceutically acceptable carrier.
54. A method of treating or preventing a disease or condition in a subject in need thereof, comprising administering to the subject an effective amount of an antibody of any one of claims 1 to 41, the antibody conjugate of any one of claims 51 to 52, or a pharmaceutical composition of claim 53.
55. A method of reducing or inhibiting abnormal cell proliferation in a subject in need thereof, comprising administering to the subject an effective amount of an antibody of any one of claims 1 to 41, the antibody conjugate of any one of claims 51 to 52, or a pharmaceutical composition of claim 53.
56. The method of claim 54 or 55, wherein the disease is a cancer.
57. The method of claim 56, wherein the cancer is a solid tumor.
58. The method of claim 56, wherein the cancer is selected from lung cancer, head and neck cancer, esophageal cancer, breast cancer, gastric cancer, colorectal cancer, bladder cancer, pancreatic cancer, skin cancer, ovarian cancer, cervical cancer, renal cancer, thyroid cancer, uterine cancer, prostate cancer, or cholangiocarcinoma.
59. The method of claim 56, wherein the cancer is selected from non-small cell lung cancer, head and neck squamous cell carcinoma, squamous esophageal cancer, breast cancer, gastric cancer, colorectal cancer, bladder cancer, pancreatic cancer, cutaneous squamous cell carcinoma, ovarian cancer, cervical cancer, renal cancer, thyroid cancer, uterine cancer, prostate cancer, or cholangiocarcinoma.1291107438300\1\AMERICASAttorney Docket No. 108843.0062460. A method of diagnosing a disease or condition in a subject in need thereof, comprising administering to the subject an effective amount of an antibody of any one of claims 1 to 41, the antibody conjugate of any one of claims 51 to 52, or a pharmaceutical composition of claim 53.
61. A composition for use in the treatment or prevention of a disease or condition, wherein the composition comprises an antibody of any one of claims 1 to 41, the antibody conjugate of any one of claims 51 to 52, or a pharmaceutical composition of claim 53.
62. A composition for use in the reduction or inhibition of abnormal cell proliferation, wherein the composition comprises an antibody of any one of claims 1 to 41, the antibody conjugate of any one of claims 51 to 52, or a pharmaceutical composition of claim 53.1301107438300\1\AMERICAS
